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Background. There is an increasing trend in the use of long-term oral anticoagulation therapy 
in children. Monitoring the international normalised ratio (INR) is an integral part in 
management of these patients, but standard laboratory testing of the INR presents challenges 
in this age group. Point-of-care INR monitors such as the Mission® PT/INR monitor provide 
advantages in efficiency and accessibility but have not been evaluated for accuracy in the South 
African paediatric setting. 
 
Objectives. This is a feasibility study with the aim to evaluate the accuracy of the Mission® 
PT/INR Monitor in comparison to standard laboratory INR measurement, in children 
presenting for INR testing. 
 
Methods. We compared the accuracy of the Mission® PT/INR monitor to the Sysmex Cs-
2100i laboratory analyser in 37 children aged between 1 year and 17 years, who presented for 
INR testing. The sample size was limited due to time constraints. 40 paired POC INR and 
laboratory INR values were obtained. 
 
Results. The majority of participants in the study were outpatients (62%) and required INR 
testing as part of screening in non-cardiac disease (81%) - the majority had chronic liver 
disease, and a minority were on warfarin therapy (13.5%). The mean INR value on the 
Mission® PT/INR was 1.49 (standard deviation (SD) 0.73) and was comparable to the Sysmex 
Cs-2100i (mean INR value 1.39 with SD 0.69). The Bland-Altman difference plot revealed 
good agreement. Bias between the two methods was 0.13 (SD 0.23). In total, 92.5% of POC 
INR values were within 0.5 units of laboratory INR value. 
 
Conclusion. The Mission® PT/INR point-of-care monitor has a clinically acceptable level of 
accuracy in children when compared with laboratory INR measurement, but larger studies are 
needed in the paediatric setting to evaluate patient safety and clinical outcomes. There is a need 
for implementing POC INR monitoring in outpatient settings but this practice will require 
robust assessment of infrastructure and quality control before application.
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CHAPTER 1:  




The twenty-first century has seen a rise in the use of anticoagulant medication for both primary 
prophylaxis and treatment of thromboembolism in children.[1,2] This trend is the result of 
advances in paediatric heart surgery and the use of life-saving therapies, including 
extracorporeal membrane oxygenation, prosthetic heart valves and central venous access 
devices. As a result, medical practitioners are increasingly required to become familiar with 
treatment strategies and the monitoring of oral anticoagulant therapy.[2] Of the oral 
anticoagulant agents available, Vitamin K antagonists (VKAs, such as warfarin) remain the 
most commonly used, with estimation of the International Normalised Ratio (INR) being a 
measure of treatment efficacy. However, therapeutic drug monitoring in children on warfarin, 
through regular phlebotomy and standard laboratory INR testing, presents unique challenges 
in the paediatric setting.[1] Fortunately, point-of-care (POC) INR measurement devices have 
been developed as a suitable alternative, and in adult populations have been shown to be 
accurate in comparison to standard laboratory INR testing and improve clinical management 
and patient-reported quality of life.[3,4] These devices have also been validated for use in 
children, but have not yet been evaluated in the South African paediatric setting. 
 
This chapter will review: 
 
1) Basics of coagulation testing in children with a focus on INR testing 
2) Current trends in VKA therapy in children 
3) Therapeutic monitoring in children on VKA therapy 
4) Description and uses of POC INR monitoring in children 
5) POC INR monitoring devices that have been researched for use in children 
6) Validation methodologies used in research on POC INR monitoring devices in children 
7) Gaps in current research on POC INR monitoring in children 
8) Background on Mission® PT/INR Monitor (Acon Laboratories) 
 
My search strategy encompassed a literature search and was performed using these databases: 
MEDLINE, Google Scholar, Clinical Key, Clinical Evidence and Pubmed. The keywords that 
were used included: Point-of-care, International Normalised Ratio, INR, coagulation, testing, 
monitoring, validation, children, paediatrics. The search yielded 3 review articles, 2 guideline 
papers and 31 studies. 
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Coagulation testing in children 
 
Blood coagulation tests are one of the most commonly requested in inpatient and outpatient 
paediatric patients. There are numerous tests available for testing the coagulation system in 
children, each of which have different indications and applications in clinical practice. These 
include tests of clotting time such as prothrombin time (PT), activated partial thromboplastin 
time (aPTT), thrombin time (TT) and reptilase time (RT) as well as various coagulation factor 
assays.[5,6] Indications for coagulation testing in paediatric clinical practice include the 
investigation of bleeding disorders, preoperative assessment of haemostasis, assessment of 
liver synthetic function and the monitoring of anticoagulation therapy for patients on VKAs 
and heparin therapy. [5,6] 
Prothrombin Time testing and International Normalised Ratio 
 
The PT assesses the extrinsic and common pathways of coagulation. It measures the time it 
takes for plasma to form a fibrin clot after exposure to tissue factor. After the addition of 
calcium to the citrated plasma solution, along with the tissue factor and phospholipid, the 
formation of the fibrin clot is detected by various means including visual, optical and 
electromechanical methods. The result is measured in seconds and is reported along with a 
control value and INR value. The normal range for the PT depends on the laboratory and 
instrument/ reagent combination - in most laboratories, the normal range is around eleven to 
thirteen seconds. [7,8] 
 
The INR value is calculated as a ratio of the patient’s PT to a control PT value, which is 
obtained using an international reference thromboplastin reagent. Therefore, as long as the 
thromboplastin reagent/ instrument system is calibrated correctly, the INR value for a particular 
blood sample will be similar in any laboratory using any thromboplastin reagent/ instrument 
system. This makes the INR test useful for VKA therapeutic monitoring as it allows 
comparison of the patient’s plasma INR at different times and from different institutions. The 
INR in a healthy adult is between 0.9-1.1. [6,7] The PT/ INR values in particular have uses in 
the evaluation of suspected bleeding disorders, diagnosis of disseminated intravascular 
coagulation, monitoring of VKA therapy and the assessment of liver synthetic function. 
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Laboratory testing of coagulation is subject to numerous quality control measures to ensure 
accurate testing. Factors related to sample collection and handling that may affect accuracy and 
are related to [6]: 
 
1) Suitability of the blood sample - plasma should be used for coagulation testing as clotting 
factors are removed with the serum preparation process; 
2) Volume of blood used - the appropriate ratio of sodium citrate to whole blood is essential 
to avoid inaccurate results - a fixed ratio of 1-part citrate to 9 parts whole blood is required 
and therefore tubes should not be over- or underfilled; 
3) Collection tube used - the light blue tube containing 3.2% sodium citrate is used as a 
standard for laboratory coagulation tests; 
4) Mixing of blood and citrate - gentle inversion to ensure appropriate mixing of citrate 
solution with whole blood is required; 
5) Elapsed time and temperature - timeous testing of the sample (to avoid degradation of 
coagulation factors), usually within 24 hours of phlebotomy is essential for accurate testing. 
Tubes are not to be frozen before testing. 
 
Other sources of interference that may lead to inaccurate results include contamination with 
intravenous solutions and anticoagulants, or interference with coagulation times due to the 
presence of lipaemia, hyperbilirubinaemia, haemolysis or polycythaemia. Various drugs and 
pathological processes may lead to a prolonged PT/INR value (Table 1) [6]. 
 
Table 1. Causes of prolonged PT/INR in children 
1) Vitamin K antagonists such as warfarin  
2) Vitamin K deficiency  
- seen in malnutrition, prolonged broad-spectrum antibiotic use and pancreatic exocrine 
insufficiency 
3) Acute and chronic liver disease  
4) Disseminated intravascular coagulation  
5) Deficiency of factors involved in the extrinsic pathway  
- may be inherited or acquired 
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6) Antiphospholipid antibodies  
 
Warfarin therapy in children 
 
VKAs, unfractionated and low molecular weight heparin are the anti-coagulant options most 
widely available for the prevention and treatment of venous and arterial thromboembolism, 
and each is associated with particular side effects. Data on the use of newer oral anticoagulants 
(e.g. direct thrombin inhibitors or Factor Xa inhibitors) in children are limited and are therefore 
less commonly used.  Table 2 shows the most common indications for anticoagulant therapy 
in children. 
 
Table 2. The most common Indications for anti-coagulant therapy in children 
Cardiac Non-cardiac 
Prophylaxis after cardiac surgery 
- Fontan surgery, Blalock-Taussig Shunt 
Primary Pulmonary Hypertension 
Mechanical prosthetic valves Acute arterial stroke 
Kawasaki Disease with large aneurysms Deep venous thrombosis 
Dilated cardiomyopathy with severe left 
ventricular dysfunction 
Anti-phospholipid syndrome 
Ventricular assist devices  
 
There are limited randomized trials in children to guide the use of oral anticoagulant therapy, 
with the majority of recommendations being extrapolated from adult literature.[2] VKAs are the 
most commonly used oral anti-coagulants in the paediatric population, and in paediatric cardiac 
patients is most commonly indicated for prophylaxis after surgery for univentricular heart 
palliation (Fontan procedure), mechanical prosthetic valves, large aneurysms following 
Kawasaki Disease, dilated cardiomyopathy with severely impaired left ventricular function and 
primary pulmonary hypertension.[2,9] Warfarin and other VKAs (known as coumarins) result 
in prolongation of PT by inhibiting the enzyme Vitamin K epoxide reductase, which is 
responsible  for converting Vitamin K epoxide (produced by the action of intestinal bacteria) 
to biologically active vitamin K. This in turn impairs the function of vitamin K-dependent 




 Figure 1. Mechanism of action of warfarin[10] 
 
Although VKAs are the most widely studied oral anticoagulant, their use presents a number of 
limitations when used for long-term therapy in children. Adverse effects include bleeding 
(most common), skin necrosis, gangrene, osteoporosis, hair loss and tracheal calcification.[2] 
The need for frequent phlebotomy for  INR monitoring in a population with inherently difficult 
vascular access adds cost and burden.  Furthermore, warfarin has numerous pharmacologic 
interactions with disease states, drugs and diet which may interact to increase the risk of 
bleeding or reduce treatment efficacy.[7] For example, infants who are breastfed are more 
sensitive to warfarin compared to infants who are formula-fed due to the lower content of 
vitamin K in breastmilk. Contraindications to warfarin therapy include previous 
hypersensitivity reactions to warfarin, severe renal or liver impairment, severe hypertension, 
infective endocarditis, pericardial effusion, active ulceration and cerebral or dissecting aortic 
aneurysm.[11]  
 
Low molecular weight heparin (LMWH), enoxaparin being the most widely studied, has 
several potential benefits in that it requires minimal monitoring, exhibits fewer drug 
interactions or dietary interference and has a reduced risk of osteoporosis and heparin-induced 
thrombocytopenia compared to other agents.  The therapeutic ranges of optimised management 
have been derived from adult data, however and the rates of major bleeding are uncertain. [12,13]  
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Minor bleeding includes bruising, epistaxis, excessive bleeding from cuts, while major 
bleeding is defined as bleeding into a major organ or requiring blood transfusion. Various 
studies describe rates of haemorrhage between 0.2 - 12.2%.[13] 
Therapeutic monitoring in children on Warfarin therapy 
 
Warfarin has a narrow therapeutic index and is subject to numerous drug and food interactions. 
Maintaining a patient’s INR within a designated therapeutic range is necessary to balance the 
risk of preventing thrombosis and embolization against the risk of bleeding and haemorrhage. 
A target INR in the range 2.0-3.0 is appropriate for most indications, including venous 
thromboembolism, atrial fibrillation and severe ventricular systolic dysfunction. In children, a 
therapeutic range of 2.0-3.0 is also recommended for aortic bileaflet mechanical valves. 
 
Time in the therapeutic range (TTR) is used as a measure for the safety and efficacy of VKA 
therapy. This refers to the amount of time a patient’s INR is within the designated target 
range.[12] This is crucial for minimising patient morbidity and mortality. Optimising the 
paediatric patient’s clinical management provides additional challenges in that drug 
pharmacokinetics, illness as well as drug and food interactions, contribute to narrow 
therapeutic windows. The frequent non-availability of paediatric drug formulations further 
complicates monitoring and reduces predictability.[13]  
 
Further challenges in therapeutic drug monitoring in children are posed by the regular 
requirement for phlebotomy so that standard laboratory-based investigations can be performed. 
This is compounded by inherently difficult venous access, in addition to relatively large volume 
of blood required to perform the test. Testing methodology is one of the variables that can lead 
to INR instability, with different testing methods using different methods for clot detection, 
different thromboplastin reagents and different sample types.[14]  
Point-of-Care Diagnostics 
 
Point-of-care (POC) INR testing refers to testing that can be performed using a device located 
near the patient as opposed to a central laboratory. A POC test is performed with a capillary 
sample placed on a strip, with a test result yielded in real time.  This capillary sample is placed 
on the strip within 30 seconds to avoid interference with the INR value as a result of tissue-
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factor release or activation of the clotting cascade.[15] Plasma or anti-coagulated whole blood 
should not be used. The monitor then uses an electrochemical method for clot detection, based 
on thrombin generation. Devices report the result as either a PT (in seconds) or as an INR.  
 
POC INR testing has been shown to provide a safe and accurate alternative to standard 
laboratory INR testing in adults and allows for rapid generation of results with resultant 
improved patient care.[3,4] POC INR monitors have also been shown to be a reliable alternative 
to lab INR testing in children, and perform well when used in a hospital or clinic setting or 
when used by patients for self-testing at home.[7,16] There are however limitations to these 
studies as large patient numbers are required to assess the risk of complications and is not 
feasible in children. 
 
POC INR Monitoring devices which have been tested in children 
 
Validation studies have been performed on many of the available POC INR monitors in 
children and have been shown to perform equally well when used within hospital/ clinic 
settings or by patients for self-testing in their homes.[7] 
 
The CoaguChek ® XS system (Roche Diagnostics) has been well studied in adult and 
paediatric patients on long-term oral anti-coagulant therapy. Moon et al compared 120 paired 
POC INR values to standard laboratory INR values in 42 children (under 16 years) with heart 
disease on anticoagulant therapy, in an outpatient setting. They found the difference in INR 
values between the two methods was consistently <0.5 with a mean difference between the two 
methods of 0.08 units. They concluded that the CoaguChek XS device is as accurate as the 
laboratory method, and faster and more convenient.[17] 
 
Bauman et al also compared the CoaguChek XS device to laboratory INR values in a smaller 
cohort of adults and children who were warfarinised with ventricular assist devices. 6 children 
and 10 adults were enrolled with 73 paired INR comparisons taken for the children cohort. The 
study found the average difference between the two methods was -0.10 (with a Bland-Altman 
95% limits of agreement -1.1;0.93). The Lin Concordance correlation coefficient (CCC) was 
0.80 (95%CI 0.60;0.92). CCC is calculated as a product of a measure of accuracy (the bias 
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correlation factor) and a measure of precision (Pearson correlation coefficient). A CCC of 1 
indicates perfect agreement.[3] They concluded that POC INR devices were moderately 
accurate in patients with VADs, but less accurate than in patients without VAD.[3] 
 
Collela et al found that the CoaguChek XS POC device underestimated the INR results by only 
0.08u (p<0.0001).[18] This evidence is supported by other studies that have found a non-
significant variability between POC devices and laboratory tests when the target range is 2-3, 
further validating the suitability of POC devices for outpatient/ home-based care. The authors 
advised caution when INR values are greater than 3.5. In such cases a confirmatory laboratory-
based INR should be performed. [19,20]  
 
Lawrie et al however found that with the CoaguChek XS INRs between 4.5-8 were comparable 
to laboratory INRs.[21] In a study on adult patients, Vazquez et al found there was poor accuracy 
for POC INR values that were greater than 3, and suggested the application of a correction 
factor in these cases to improve accuracy.[22] Moiz et al found overall good accuracy with the 
CoaguCheck XS Pro, and found that the discrepancy in results in only 11 of the 200 INR 
samples led to differences in dosing decisions.[23] 
 
In South Africa, a study by Benade et al compared the accuracy of the CoaguChek XS monitor 
with that of a standard laboratory analyser in 304 adult patients on standard warfarin therapy, 
who presented for routine INR testing. The study found the mean INR results between the two 
methods to be comparable with good agreement on Bland-Altman difference plot analysis as 
long as readings were in the target range (2.0 - 3.5). The difference between the two methods 
showed increased variability when the INR on the laboratory analyser was greater than 3.5.[4] 
 
The CoaguChek S device has also been studied for home monitoring of oral anticoagulant 
therapy in children. Hill et al compared in 129 paired INR samples in children under 18 years 
of age, on long-term anti-coagulant therapy in an outpatient setting. They found the overall 
intraclass correlation coefficient between the CoaguChek S and standard laboratory method 
was 0.75 (95%CI 0.66-0.82) and that on average the POC INR device underestimated INRs by 
0.11 (+/- 0.54 units), but that for lab INRs of 3.5 units or higher, the POC device overestimated 
the value by 0.49 (+/- 1.09 units). They concluded that the CoaguChek S is valid for in-home 




The INRatio2 PT/INR monitor (Alere Ltd) was previously recommended by the National 
Institute for Health Care Excellence for self-monitoring in children and adults on long-term 
anticoagulant therapy but in 2015 the device was withdrawn from the market as there were 
reported incidents of device malfunction and as well as reported INR results that were lower 
than expected.[24] The problem of under-reading by the INRatio PT/INR was raised when the 
results of the Re-LY trial were published in 2009. This was a multi-centre non-inferiority study 
comparing the safety and efficacy of warfarin to a novel anti-coagulant dabigatran in patients 
with non-valvular AF.[25] The study found that while both high- and low-dose dabigatran were 
associated with fewer strokes than warfarin therapy, it was noted that there was a lower than 
expected rate of INR control in the warfarin group (measured as time in therapeutic range, 
TTR), which could not be explained just by the fact that there was higher enrollment of Re-LY 
participants who had not been on long-term VKA therapy. Other important assessments of INR 
control were also not reported in the study, including local ISI calibration and external quality 
control of INRs. Since being removed from the market, no replacement device has as yet been 
released for the INRatio2 PT/INR monitor. 
 
Other devices that are available on the international market include CoagMax (Microvisk) - no 
studies have as yet been published on this device; and microINR (iLine microsystems) with 
several published studies showing mixed results on the performance of the device. [26,27] 
Clinical Settings in which POC INR Devices have been researched 
 
Three different settings for POC INR monitoring and management in patients on long-term 
anticoagulant therapy have been utilized [28]: 
 
1) POC INR testing within a health care facility where immediate results are obtained and 
instructions on dosage are given to patients [1]; 
2) POC INR testing at home with results phoned to a health facility or practitioner who 
provides instructions on drug dosing (i.e. self-testing); 
3) POC INR testing at home with patients adjusting their own drug dosing based on a pre-
determined dosing nomogram (i.e. self-management); 
 
 19 
POC INR monitoring within the home (also known as POC INR Home Testing, PIHT) has 
been shown to be a feasible method of INR testing and is associated with non-inferior warfarin/ 
INR control compared with standard laboratory monitoring.[3] Methodological limitations in 
study designs make it difficult to measure true safety and efficacy in monitoring of oral 
anticoagulant therapy in children. As a result, TTR is commonly used as a surrogate measure 
for safety and efficacy of warfarin therapy.[3] Christensen et al provided a review of studies 
which evaluated POC INR Home Testing (PIHT) with self-testing and found that TTR 
compared favorably with laboratory monitoring (63-83% vs 50%).[29] 
 
Patient self-management has been evaluated in numerous studies - in one randomized 
controlled trial (where patients were randomized to continue self-testing or self-management), 
TTR was similar in both groups (83%) with patients in the self-management group reporting 
higher health-related quality of life and satisfaction with therapy.[30] 
 
While potential advantages of using POC INR testing in children on long-term anti-coagulant 
therapy include greater convenience to patients with resultant improvement in treatment 
compliance and more frequent monitoring, patients may experience increased anxiety about 
their disease and coagulation monitoring. Furthermore limitations to the use of POC devices 
include the cost of the device, the need for specialized training and strict adherence to quality 
standards outside of the clinical laboratory setting. [6,31] 
 
POC devices are already in use for home-based self-management in Europe and Australia with 
patients describing higher quality of life and satisfaction with therapy. Bauman et al have 
described home-based management and self-testing programs where TTR was 83%.[3] 
POC testing in the South African setting 
 
POC INR testing is of particular value in resource-limited settings, where it can provide rapid 
real-time INR results, and can be used in the home-setting, thereby reducing cost and 
improving patient care. This is especially relevant in the South African setting where rural or 
remote locations require patients to travel great distances in order to have centralized INR 
testing done for therapeutic monitoring. Red Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town provides services to children on long-term warfarin, not only from 
the Cape Town Metropole but from across the Western Cape and neighbouring provinces. 
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Some of these patients travel from far with paid-for transport to have their INR tested at the 
central laboratory and to be evaluated by clinicians. 
 
Devices have previously been validated in the South African setting in adults on long-term oral 
anticoagulant therapy and have been shown to be accurate and precise, although accuracy and 
precision tend to decrease with INR values above 4.5-5.0. As mentioned, the CoaguChek XS 
has been shown to be accurate for use in a tertiary hospital outpatient setting for adults on long-
term warfarin therapy. It is suggested that the CoaguChek XS monitor be utilised in a clinic 
setting as a screening tool for patients on long-term oral anticoagulant therapy, but that a 
vigorous quality-control system would be needed.[4] The microINR POC INR monitor was 
evaluated in adults on warfarin therapy who presented for INR testing at a tertiary academic 
setting and was found to be accurate and precise.[32] The Coag-Sense INR system was evaluated 
in 202 adults on warfarin therapy and found to be adequate in terms of accuracy, although the 
test strip error rate was found to be high.[32] 
 
No studies have as yet been published which evaluate the use of POC INR monitors in a 
paediatric setting in South Africa. Although the absolute number of paediatric patients on long-
term warfarin therapy is far less than that of adults, the number of children on warfarin therapy 
is increasing. A study evaluating the validity of POC INR monitors in the South African 
paediatric setting would be relevant considering the large number of our paediatric patients 
who live in remote areas as well as the inherent difficulties with obtaining regular INR samples 
by phlebotomy in the paediatric group. A POC INR monitor validated for use in South African 
children would contribute to our knowledge of therapeutic monitoring which reduces the 
financial cost of travelling far distances for centralized INR laboratories (thereby reducing the 
cost to the lab as well), as well as the cost of missed school days and workdays. POC INR 
monitors would also allow more frequent testing in an age group in which warfarin has 




Two main methodological differences exist in comparing the POC INR devices to lab INR 
measurements. One technique uses whole blood for testing with the POC INR monitor 
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(obtained while doing phlebotomy) while the other uses a capillary sample (obtained by 
fingerprick). 
 
Clinically relevant agreement between INR pairs has previously been determined as[33]:  
 
1) Both INR values are within the therapeutic range, or 
2) Both values are above or below the therapeutic range, or 
3) Only one value is within the therapeutic range, yet the pair are within 0.4 units of each 
other 
 
The POC INR is collected according to standard technique (as prescribed by the manufacturer 
of the POC INR device) by a trained phlebotomist, using a single fingerprick (with a lancet) 
and collecting the capillary sample on a device-specific test strip. The POC INR result is 
obtained within 1 -2 minutes, depending on the device used. This is followed sequentially by 
collection of the standard laboratory INR sample as a venous blood sample drawn into a 3.2% 
citrate tube. The laboratory INR specimen is delivered to a central laboratory for analysis using 
standard operating procedures including quality control measures. [1,4] Ideally, the paired 
samples are collected within 1 hour of each other and the laboratory INR sample is delivered 
to the lab within 30 mins of collection. Some studies report collecting the POC INR result on 
the same day as the laboratory INR was collected.[3] 
 
Bauman at al found that the CoaguChek XS INR measurements were accurate compared with 
laboratory INR measurements when venous whole blood was used on the POC device. Two 
separate pairs of readings were obtained from 62 children. Bland-Altman's 95% limits of 
agreement were 0.11 (-0.20; 0.42) and 0.13 (-0.22; 0.48) at the two time points, respectively.[34] 
The accuracy of the POC monitor using capillary blood was evaluated by Karon et al when 
they compared the accuracy of capillary whole blood INR on several different devices 
including the CoaguChek XS.[35] They found more than 90% of results on the CoaguChek XS 
were within 0.4 INR units of the reference laboratory method. 
 
In reporting and comparison of POC INR and laboratory results, agreement between the results 
is evaluated using standard difference plots. The average and limit of agreement between the 
two methods is often demonstrated in the Bland-Altman difference plot, reported with 95% 
limits of agreement.[35] Some studies report the Lin’s concordance correlation coefficient 
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(CCC) to assess the agreement between the POC INR value and the laboratory INR value, as 
described above.  
Mission® PT/INR monitor from Acon Labs 
 
In this feasibility study, we used the Mission® PT/INR monitor from Acon laboratories (San 
Diego, USA) which was released for use in South Africa in 2016. The battery- or AC power-
operated handheld device is marketed as suitable for use by medical professionals and for home 
testing.  
 
It uses individually packaged, uniquely calibrated test strips which do not require refrigeration 
and have a shelf life of 2 years. The strips are impregnated with recombinant human 
thromboplastin with an international sensitivity index (ISI) of 1.0. Specific instructions are 
included on optimal conditions for obtaining the fingerprick sample to ensure an accurate 
result. After depositing a single drop of capillary blood on the test strip (or 15 microlitres of 
venous whole blood) it reports PT and INR results within 2 minutes and can report INR results 
between 0.7 and 7.0. Clot detection is by optical fluorescence. No result is displayed if internal 
quality control conditions are not met or if an inadequate volume of capillary blood is deposited 
on the strip.  
 
Validation studies have been performed on adult patients in the Unites States. The Clinical 
Comparison report published by Acon Laboratories (San Diego, USA) in 2016, reported on the 
results of paired POC INR- laboratory INR values in 219 volunteer adult subjects (180 on long-
term oral anticoagulant therapy) across four different clinical sites. The accuracy-performance 
component of the study found that the POC INR results met overall acceptance criteria for 
capillary blood samples at all four sites. The precision study found that acceptance criteria were 
met at only three of the sites. 
 
The Mission® PT/INR device has been validated in a tertiary hospital outpatient adult setting 
in Johannesburg, South Africa. In a study by Louw et al, INR measurement was obtained by 
POC INR monitor and measured by standard laboratory analyser (STAGO STA-R Max 
laboratory analyser) in 329 adult patients on long-term warfarin therapy.[36] The study found 
the Mission PT/INR device to be accurate and showed for expanded and narrow clinical 
agreement across a range of INR values (1.2-6.0). A deviance between values greater than 4.5 
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was not demonstrated. The results obtained by the Mission PT/INR device were also shown to 
be reproducible. The authors recommended that POC INR devices be validated individually in 
the context that they are to be used and that clinical implementation will require guidelines to 
guide as to which results need repetition or formal laboratory testing.  
Conclusion 
 
POC INR monitors have been shown to be accurate in children in comparison to standard 
laboratory INR measurement within a narrow range of values, although outside of this range 
values are less predictable. However, there are no high-quality studies comparing the rate of 
complications in those using POC INR monitors to those monitored with laboratory INR 
measurement. This is owing mainly to methodological difficulties in study designs in children. 
 
There have been no studies validating the accuracy of POC INR monitors in South African 
children, a group who in particular would benefit from this technology. A validated instrument 
for POC INR testing in the paediatric population would assist in reducing time and costs to 
both patient and hospital, as well as ensuring effective and acceptable health care. Based on 
the needs of a growing number of our patients at RCWMCH, we undertook a validation study 
of the Mission PT/INR monitor in children presenting for INR testing at our institution. This 
study aimed to determine the accuracy of the portable POC INR monitor in comparison to the 
current standard of care laboratory measurement of the INR value, in the unique setting of Red 
Cross War Memorial Children’s Hospital (RCWMCH), a tertiary paediatric facility. 
 
In addition, we described a number of other secondary variables, including patient 
demographics and disease profile, and compared logistical parameters such as time of 
sampling and time of result availability to help make inferences about costs incurred for 
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Background. There is an increasing trend in the use of long-term oral anticoagulation therapy 
in children. Monitoring the international normalised ratio (INR) is an integral part in 
management of these patients, but standard laboratory testing of the INR presents challenges 
in this age group. Point-of-care INR monitors such as the Mission® PT/INR monitor provide 
advantages in efficiency and accessibility but have not been evaluated for accuracy in the South 
African paediatric setting. 
Objectives. This is a feasibility study with the aim to evaluate the accuracy of the Mission® 
PT/INR Monitor in comparison to standard laboratory INR measurement, in children 
presenting for INR testing. 
Methods. We compared the accuracy of the Mission® PT/INR monitor to the Sysmex Cs-
2100i laboratory analyser in 37 children aged between 1 year and 17 years, who presented for 
INR testing. The sample size was limited due to time constraints. 40 paired POC INR and 
laboratory INR values were obtained. 
Results. The majority of participants in the study were outpatients (62%) and required INR 
testing as part of screening in non-cardiac disease (81%) - the majority had chronic liver 
disease, and a minority were on warfarin therapy (13.5%). The mean INR value on the 
Mission® PT/INR was 1.49 (standard deviation (SD) 0.73) and was comparable to the Sysmex 
Cs-2100i (mean INR value 1.39 with SD 0.69). The Bland-Altman difference plot revealed 
good agreement. Bias between the two methods was 0.13 (SD 0.23). In total, 92.5% of POC 
INR values were within 0.5 units of laboratory INR value. 
Conclusion. The Mission® PT/INR point-of-care monitor has a clinically acceptable level of 
accuracy in children when compared with laboratory INR measurement, but larger studies are 
needed in the paediatric setting to evaluate patient safety and clinical outcomes. There is a need 
for implementing POC INR monitoring in outpatient settings but this practice will require 
robust assessment of infrastructure and quality control before application.
 
There are a growing number of children 
requiring long-term oral anticoagulant 
therapy, a trend which is largely the result 
 
of advances in paediatric heart surgery and 
the use of life-saving therapies, including 
extracorporeal membrane oxygenation, 
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prosthetic heart valves and central venous 
access devices. The most commonly used 
oral anticoagulant in children remains the 
Vitamin K antagonist, warfarin. [1,2] Table 1 
shows common indications for long-term 
oral anticoagulant therapy in children. 
Warfarin has a narrow therapeutic index 
and is sensitive to various interactions with 
disease states, drugs and foods. 
Furthermore, genetic polymorphisms in the 
clotting pathways also affect the 
metabolism of warfarin. As a result, 
children on long term warfarin therapy 
require regular monitoring of the 
International Normalised Ratio (INR) to 
ensure that it remains within a narrow 
therapeutic range. For most indications the 
target range is 2.0-3.0, while for children 
with mechanical heart valves the target 
range is 2.5-3.5.[3] Regular phlebotomy to 
allow for INR measurement at standard 
laboratory analysers poses a challenge in 
the paediatric population and is 
compounded by inherently difficult venous 
access, in addition to the relatively large 
volume of blood required to perform the 
test. The frequent non-availability of 
paediatric drug formulations further 
complicates monitoring and reduces the 
predictability of regular dosing.[4]   
Point-of-care (POC) INR measurement 
devices have been developed as a suitable 
alternative to standard laboratory-based 
testing, and in adult populations have been 
shown to be accurate in comparison to 
standard laboratory INR testing and 
improve clinical management and patient- 
reported quality of life.[5,6] Further abroad, 
these devices have also been validated for  
use in and have been found to be accurate 
and reliable for “patient self-testing” at 
home, with telephonic guidance from a 
health provider, as well as for “patient self-
management” according to a standardized 
dosing nomogram. POC devices are already 
in use for paediatric home-based self-
management in Europe and Australia with 
patients describing higher quality of life 
and satisfaction with therapy.[6] Previously 
validated POC INR devices were shown to 
be accurate within a narrow range but 
showed greater deviations from laboratory 
INR values above 4.5.[7,8] 
POC INR devices have as yet not been 
evaluated for use in the South African 
paediatric setting, where its advantages 
may be especially relevant as many patients 
live in rural or remote locations and are 
required to travel great distances in order to 
have centralized INR testing. The Red 
Cross War Memorial Children’s Hospital 
(RCWMCH) in Cape Town, South Africa 
provides services to children on long-term 
warfarin therapy, not only from the Cape 
Town Metropole but from across the 
Western Cape and neighbouring provinces. 
Some of these patients travel from far with 
paid-for transport to have their INR tested 
at the central laboratory and to be evaluated 
by clinicians. The advantages of using POC 
INR testing in children include a smaller 
blood volume required for testing (15  
microlitres obtained by finger-prick), 
smaller turnaround time for results, reduced 
need for taking time out of school or time 
off work, reduced cost of travelling and 
reduced cost to central laboratories for 
testing formal INRs. 
Table 1. Common indications for oral anticoagulant therapy in children 
Cardiac Non-cardiac 
Prophylaxis after cardiac surgery 
- Fontan surgery, Blalock-Taussig Shunt
Primary Pulmonary 
Hypertension 
Mechanical prosthetic valves Acute arterial stroke 
Kawasaki Disease with large aneurysms Deep venous thrombosis 
Dilated cardiomyopathy with severe left ventricular dysfunction 
Anti-phospholipid 
syndrome 
Ventricular assist devices 
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There a numerous POC devices 
available, and the Mission® PT/INR device 
(Acon Laboratories, San Diego, USA) has 
been evaluated in the South African adult 
outpatient setting.[9] This portable device 
was released in South Africa in 2016 and 
uses individually packaged, uniquely 
calibrated test strips which do not require 
refrigeration and have a shelf life of 2 years. 
Specific instructions are included on 
optimal conditions for obtaining the 
fingerprick sample to ensure accurate 
results. 
The aim of this study was to evaluate the 
Mission® PT/INR POC INR testing device 
for accuracy in a South African tertiary 
paediatric setting at RCWMCH. In 
addition, we described secondary variables, 
including patient demographics and disease 
profile, and compared logistical parameters 
such as time of sampling and time of result 
availability to help make inferences about 
costs incurred for patients, their families 
and the health system.  
This report was structured according to 
the guidelines in the STARD checklist 
(Standards for Reporting Diagnostic 
accuracy studies), and all aspects of those 
guidelines have been included herein. 
Methods 
Study design and participants 
The study was performed as an 
observational descriptive study based at 
RCWMCH, a tertiary paediatric facility in 
Cape Town, South Africa. It served as a 
feasibility study to lay the groundwork for 
future data collection. Eligible participants 
included all children aged between 12 
months and 18 years of age who presented 
at the facility for INR testing, regardless of 
the indication or diagnosis. In order to be 
eligible for enrolment, participants had to 
be accompanied by a consenting primary 
caregiver. Both inpatients and outpatients 
were eligible and blood samples were 
collected at different sites in the hospital 
including the National Health Laboratory 
Service (NHLS) phlebotomy area, inpatient 
wards and outpatient clinics. Very young 
children (under 12 months of age) and 
critically ill children (located in the Medical 
Emergencies Unit or Paediatric Intensive 
Care Unit) were excluded from enrolment. 
The primary care giver participants 
received a participant-information sheet in 
the language of their choice (English, 
Afrikaans or isiXhosa), and gave voluntary 
informed consent. Assent was obtained in 
addition from children aged 5 years or 
older. Children who refused assent were not 
included in the study - there was one such 
case (in a child older than 7 years of age). 
The sample size of paired samples was 
calculated based on interclass correlation of 
5% and confidence interval of less than 5% 
- this value was calculated as n=138 paired
tests. Due to time constraints, only a limited
sample number of paired samples were
obtained. 37 eligible children were enrolled
with 40 paired POC INR and standard
laboratory INR measurements obtained.
Repeat sampling on the same patient was
allowed where repeat INR measurements
were ordered by the managing clinician.
Ethics approval was obtained from the 
Human Research Ethics Committee 
(HREC) of the University of Cape Town 
(HREC reference no. 730/2018). 
Study protocol 
Blood samples for INR analysis were 
obtained consecutively by venepuncture 
(by a trained phlebotomist or by hospital 
medical staff) for collection in citrated 
tubes (1.8 ml BD Vacutainer from BD-
Plymouth, PL6 7BP, UK - containing 0.2 
mL 3.2% sodium citrate) for measurement 
on the Sysmex CS-2100i (Sysmex, Kobe, 
Japan) coagulation analyser in the 
laboratory and then by fingerprick (done by 
the investigator) for measurement on the 
Mission® PT/INR device. All venous 
blood INRs were processed at the 
laboratory within 5 hours of collection. 
The venous INR samples were analysed 
on the Sysmex CS-2100i coagulation 
analyser using standard operating 
procedures including the performance of 
internal quality control material. This 
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analyser system uses Thromborel®S 
(Siemens Healthcare diagnostics, 
Tarrytown, USA) as a reagent and employs 
a photo-optic method of clot detection, with 
multiwavelength scanning to correct for 
samples affected by haemolysis, icterus or 
lipaemia which may interfere with the 
assay. 
All Mission® PT/INR values were 
obtained by the investigator who had 
training in appropriate use of the device 
according to the manufacturer’s guidelines. 
This device and associated supplies were 
provided by the regional Acon 
representative.  Capillary blood (around 10 
- 30 microlitres) was obtained by a
fingerprick and applied to test strips and
tested on the Mission® PT/INR device. The
strips are impregnated with recombinant
human thromboplastin with an international
sensitivity index (ISI) of 1.0. After
depositing a single drop of capillary blood
on the test strip it reports PT and INR
results within 2 minutes and can report INR
results between 0.7 and 7.0. Clot detection
is by optical fluorescence. No result is
displayed if internal quality control
conditions are not met or if an inadequate
volume of capillary blood is deposited on
the strip.
Main outcome measures and method 
comparison 
Primary outcome values that were 
measured were the values of paired POC 
and laboratory INR values. The INR results 
obtained for the two methods were 
compared to establish accuracy of the POC 
INR device. Where participants were on 
warfarin therapy, their doses were adjusted 
(by the primary managing clinician) 
according to the standard laboratory INR 
result. We recorded the times of either 
sample collection, time of authorization and 
time of result availability, as well as the 
location of sample collection. Furthermore, 
we recorded secondary variables such as 
patient demographics and disease profile 
(as they related to the indication for INR 
sampling), and details of current anti-
coagulation therapy. 
Data management and statistical 
analysis 
Participants were assigned a sequential 
study number and data were initially 
captured anonymously on hard copy and 
then transferred to an electronic database 
for storage and maintenance (RedCap® 
database). Results were then collated on a 
spreadsheet and graphically summarised 
using standard descriptive statistical 
techniques. 
We expressed continuous data variables 
as mean ±SD, percentage or coefficient of 
variation, as appropriate. A Bland-Altman 
plot to assess the magnitude of agreement 
was obtained between the two methods. A 
p-value of 0.05 was considered significant.
Statistical analyses were performed using
Stata 15.1 (Statacorp®).
We used the Wilcoxon signed-rank test 
to compare paired INR values, and 
Spearman’s rank correlation to correlate the 
results from the two methods. Finally, the 
accuracy of POC values was determined by 
comparison to the INR values from the 




Thirty-seven patients were enrolled into the 
study, with forty paired POC INR and 
laboratory INR values. Therefore, three 
patients had a second INR taken during the 
course of the study. Table 2 shows the 
demographic profile of the study sample.  
Two thirds of the study sample were males, 
with a spread across the age ranges, 
although the majority were older than 7 
years of age and able to provide written 
assent for participation in the study. Most 
were outpatients at the time of testing.  
Although the majority of participants 
hailed from the Cape Town Metropole, 
there were a significant number who 
resided outside of Cape Town and even 
from outside the province. Although the 
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sites of sample collection tended to be in an 
outpatient setting, not all samples were 
collected in the setting that reflected the 
hospital admission status of the participant. 
Table 3 summarises the disease profile 
of the participants in the study sample. The 
minority of participants had their INRs 
tested for primary cardiac indications (19% 
vs 81%). Most of those were known cardiac 
patients, more than half having had cardiac 
surgery. Two participants were newly 
diagnosed with dilated cardiomyopathy 
(DCMO) and one participant with an 
unoperated complex cardiac lesion had INR 
testing as a screening measure prior to a 
cardiac catheterisation procedure. 
Non-cardiac indications for INR testing 
predominated in the study sample. The vast 
majority of these patients had liver disease 
as the primary indication for INR testing, 
most of whom had chronic liver disease 
related to biliary atresia. Only one patient 
had underlying venous thromboembolism 
as the primary indication for INR testing. 
The remainder of the participants had INR 
testing as a screening measure - ten had 
INR testing to exclude a bleeding disorder 
(recurrent epistaxis, easy bruising, 
haematuria, family history of bleeding 
disorder, acute pancreatitis with DIC), two 
patients known with cystic fibrosis had INR 
testing as part of a screen for liver disease, 
one had routine INR screening pre-
procedure, and one had INR testing after 
ingestion of a toxin with anti-coagulant 
properties. 
The minority of participants had 
comorbidities that were not related to the 
primary indication for INR testing. There 
were no HIV positive patients and only one 
patient had confirmed pulmonary 
tuberculosis. The remaining participants 
had systemic disorders including endocrine 
abnormalities or immunologic diseases. 
Profile of anticoagulant therapy 
Five patients (13.5%) were on 
anticoagulant therapy including four on 
warfarin therapy and a fifth on aspirin. The 
dosing schedules for the participants on 
warfarin varied. Four of these participants 
were on 2,5 milligrams doses, each at 
varying weekly frequencies - varying from 
3 times per week to 7 times per week. One 
participant was on 2.0 milligrams of 
warfarin 7 times per week. Warfarin was 
dispensed as 5 mg tablets which patients 
were instructed (by the pharmacy team) to 
disperse in a measured volume of water and 
then to draw up and administer the correct 
dose. 
Details of sample collection 
All laboratory INR samples were received 
by the laboratory on the same day as sample 
Table 2. Demographic profile of study sample 
Total number of participants n=37  N (%)   
N (%) 
Gender 
Male 23 (62) 
Female 14 (38) 
Age (years, months) 
Youngest 1y 1m 
Oldest 17y 
Mean 8y 
 < 5 years 10 (27) 
5 - 6 years 5 (13.5) 
>7 years 22 (59.4) 
Hospital admission status 
Inpatient 14 (38) 
Outpatient 23 (62) 
Primary Place of Residence 
Cape Town Metropole 26 (70) 
Western Cape (other than Cape Town) 7 (19) 
Not from Western Cape 4 (11) 
Place of Sample Collection 
Outpatient clinic 4 (11) 
Inpatient Wards 15 (40) 
Ambulatory Medicine department 3 (8) 
Laboratory phlebotomy department 15 (40) 
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collection - the average time to receipt by 
the laboratory was 32 minutes with a 
minimum time to receipt 0 mins while the 
maximum time to receipt was 4 hours 8 
mins (IQR: 8 - 46 minutes). For one sample 
there was no time of collection available. 
The average time to INR result 
authorisation after receipt by the laboratory 
was 1 hour and 33 minutes (minimum 26 
minutes, maximum 2 hours 34 minutes). 
All POC INR samples were obtained within 
5 hours of laboratory INR sampling. The 
average time delay between POC INR and 
laboratory INR sampling was 1 hour 13 
mins (min 6 minutes, maximum 4 hours 33 
minutes). There was no time of collection 
available for 1 laboratory sample. The 
average time to POC INR result on the 
Mission® PT/INR device was 55 seconds. 
Method comparison analysis 
Table 4 summarises the comparison of the 
Mission® PT/INR and laboratory INR 
results. 
The mean INR values for the Mission® 
PT/INR and the laboratory method 
compared favourably with means of 1.49 
(SD 0.73) and 1.39 (SD 0.69) respectively 
(Table 4) - this represents a slight 
overestimation of INR values by the 
Mission® PT/INR device. Non-parametric 
tests showed that this slight overestimation 
was statistically significant (p-value 
0.0012). 92.5 % of INR readings INR 
results on the POC INR device were within 
0.5 units of the laboratory value.  
The limit of agreement between the two 
methods of INR measurement are 
represented in the Bland-Altman difference 
plot (Figure 1) - this revealed good 
agreement with mean difference of 0.13 (-
0.33; 0.58). Only two values were outside 
the 95% limits of agreement. 
Discussion 
In this feasibility study we sought to 
compare the accuracy of the Mission® 
PT/INR device to standard laboratory INR 
measurement, as well as describe the 
characteristics of the population of children 
who require INR monitoring at RCWMCH.  
Although the study sample was small, 
comparison of the accuracy of the 
Mission® PT/INR to laboratory INR 
testing showed good agreement over a wide 
range of INR values. This is in keeping with 
previous studies on the device in adults.[9]  
We found that the majority of the 
children who required INR testing required 
INR testing for screening purposes in non-
cardiac related illness, as opposed to 
monitoring of oral anticoagulation therapy. 
This is not unexpected as the absolute 
number of children under the age of 18 on 
long term oral anticoagulation is much 
Table 3. Disease profile of study sample 
Total number of participants  
n=37 N (%) 
Primary indication for INR 
testing 
CARDIAC 7 (19) 
   Fontan/Glenn circulation 1 (2.7) 
   Dilated cardiomyopathy 2 (5.4) 
   Prosthetic Valve 3 (8.1) 
   Kawasaki Disease 0 
   Primary Pulmonary    
Hypertension 0 
   Other 1 (2.7) 
   Known cardiac patient? 5 (13.5) 
NON-CARDIAC 30 (81) 
   Liver Disease 13 (35.1) 
   Renal Disease 2 (5.4) 
   Venous Thromboembolism 1 (2.7) 
   Arterial Thromboembolism 0 
   Other 14 (37.8) 
Comorbid illnesses 6 (16.2) 
HIV 0 
TB 1 (2.7) 
Renal 0 
Liver disease 0 
Malignancy 1 (2.7) 
Haematological 0 
Other 4 (10.8) 
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lower than the number of adult patients. 
The indications were varied but patients 
with chronic liver disease made up the 
majority.  
The majority of patients requiring INR 
testing were outpatients and a significant 
proportion of these were from outside the 
Cape Town metropole. These findings are 
testament to the possible role that POC INR 
testing could play in an outpatient setting. 
A validated POC INR device could be used 
in peripheral clinic settings with the 
assistance of a health professional (such as 
a nurse or community doctor) and therefore 
save much in the way of patient and health 
service burden and finances. Such an 
endeavor will require further validation of 
individual devices at these settings with 
adequate training of both health care 
provider and patient to ensure quality 
assurance. Training protocols and training 
programmes have been developed by 
consensus recommendation and are already 
employed in paediatric communities in 
Europe and Australia.[6]  
A comparison of the turnaround times to 
results for the two methods demonstrated 
the benefit that a rapid, real time INR 
measurement device would have for 
patients. In our setting, many travel from 
outside the metropole and wait for hours in 
busy outpatient units and day wards for 
their INR result so that appropriate dosage 
adjustment to warfarin therapy can be 
made. This time-consuming exercise 
presents a cost to patients financially in 
terms of workhours lost, as well as time out 
of school, and is a burden to busy central 
laboratories. Delays in time to obtaining the 
laboratory INR result is further complicated 
by delays in sending collected specimens to 
the lab. 
The sample size was too small to allow 
for a meaningful evaluation of device 
accuracy in the cohort of patients on oral 
anticoagulant therapy. Future evaluation of 
the accuracy of POC INR testing in the 
cardiac cohort of children will require a 
larger study sample and probably 
expansion of the study to other INR testing 
sites to ensure an adequate sample size for 
power analysis.  
The research was conducted as part of a 
master degree in medicine, and as such the 
sample size was subject to time limitations. 
Data were collected and analysed as a pilot 
study, with further data collection to be 
completed by the research team going 
forward. The small sample size limited our 
ability to demonstrate increased variability 
in the difference between methods at higher 
INR values, as has been reported in other 
devices.[7,8] We were not able to perform 
advanced statistical and linear regression 
calculations on the basis of our small 
sample size, and this analysis should be the 
subject of future studies which expand on 
the cohort size.   
There were four instances of error 
messages produced by the device during 





All INR results, N (%) 40 (100.0) 40 (100.0) 
   Mean INR (SD) 1.49 (0.73) 1.39 (0.69) 
   Mean difference (SD) 0,13 (0,23) 
   % within 0.5 units 92.5 
INR <1.0, n (%) 6 (15.0) 12 (30.0) 
   Mean INR (SD) 0,82 (0,10) 0,95 (0,05) 
   Mean difference (SD) 0,11 (0,19) 
INR 1.0-1.9, n (%) 27 (67.5) 22 (55.0) 
   Mean INR (SD) 1,29 (0,17) 1.20 (0,23) 
   Mean difference (SD) 0,12 (0,23) 
INR 2.0-2.9, n (%) 5 (12.5) 4 (10.0) 
   Mean INR (SD) 2.40 (0,26) 2.26 (0,19) 
   Mean difference (SD) 0,17 (0,21) 
INR 3.0-3.9, n (%) 1 (2.5) 1 (2.5) 
   Mean INR (SD) 3.80 3.17 
   Mean difference (SD) 
INR 4.0-4.9, n (%) 1 (2.5) 1 (2.5) 
   Mean INR (SD) 4.00 4.25 
   Mean difference (SD) 
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fingerprick sampling. After discussion with 
the local distributor, these appeared to be 
related to the volume of blood sample 
collected or due to contamination of the 
blood sample (due to dirt on the subject’s 
fingers). This occurrence highlighted the 
need for external quality control and 
support by the device manufacturers and 
distributors for future use of the Mission® 
PT/INR device. 
This study is the first to evaluate the 
accuracy of POC INR devices in a 
paediatric population in South Africa. 
Although the study sample was small, it 
provided insight into the profile of children 
requiring INR testing a tertiary paediatric 
setting in South Africa. As such it has 
highlighted the need to extend this 
feasibility study further with collaborative 
data collection at multiple sites, either 
simultaneously or contiguously.  
Conclusion 
This feasibility study showed that the 
majority of patients at RCWMCH who 
required INR testing, did so for screening 
purposes in non-cardiac disease, with a 
minority of patients on long-term oral 
anticoagulation. The Mission® PT/INR has 
been shown to be accurate in a wide range 
of readings but follow-up research with a 
larger study sample is required to provide a 
power analysis of the accuracy of this 
device in a tertiary hospital paediatric 
setting. This study has laid the groundwork 
for such research. 
Furthermore, this study has shown that 
this POC INR device may be implemented 
in an outpatient setting (including 
peripheral clinics) but that a detailed 
assessment of the infrastructure and 
capacity of such settings will be required to 
allow for appropriate and reliable quality 
control processes. Before implementation, 
staff will require training on optimal use 
and troubleshooting of the device, 
preferably according to a standard 
operating procedure, which should address 
how to proceed if INR readings fall outside 
of a prescribed range. 
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Figure 1. Bland-Altman analysis - 95% confidence intervals indicated (grey), 
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The twenty-first century has seen an increase in the use of anticoagulant medication for both 
primary prophylaxis and treatment of thromboembolism in children. Advances in paediatric 
heart surgery and the use of life-saving therapies, including extracorporeal membrane 
oxygenation, prosthetic heart valves and central venous access devices have contributed to 
this trend. Medical practitioners are increasingly required to become familiar with treatment 
strategies and the monitoring of anticoagulant therapy. 
There are limited randomized trials in children to guide the use of oral anticoagulant therapy, 
with the majority of recommendations being extrapolated from adult literature (Jain and 
Vaidyanathan 2010). Vitamin K antagonists (VKA, such as warfarin) are the most commonly 
used oral anti-coagulants in children. The most common indications for the use of these 
agents include prophylaxis after surgery for univentricular heart (Fontan procedure), 
mechanical prosthetic valves, large aneurysms following Kawasaki Disease, dilated 
cardiomyopathy with severely impaired left ventricular function and primary pulmonary 
hypertension (Jain and Vaidyanathan 2010).  
Contraindications to warfarin therapy include hypersensitivity to warfarin, severe renal or 
liver impairment, severe hypertension, infective endocarditis, pericardial effusion, active 
ulceration and cerebral or dissecting aortic aneurysm (Vitale, De Feo et al. 1999). 
VKAs, unfractionated and low molecular weight heparin are the anti-coagulant options most 
widely available, and each is associated with particular side effects. Data on the use of newer 
oral anticoagulants (e.g. direct thrombin inhibitors or Factor Xa inhibitors) in children are 
limited and are therefore less commonly used.  VKAs remain the only oral agent available, 
with estimation of the International Normalised Ratio (INR) being a measure of treatment 
efficacy.  
Maintaining a patient’s INR within a designated therapeutic range is necessary to balance the 
risk of preventing thrombosis and embolization against the risk of bleeding and haemorrhage. 
Time in the therapeutic range (TTR) is used as a surrogate measure for the safety and 
efficacy of VKA therapy. This refers to the amount of time a patient’s INR is within the 
designated target range (Jones, Newall et all 2011). This is crucial for minimising patient 
morbidity and mortality. 
Low molecular weight heparin (LMWH), enoxaparin being the most widely studied, has 
several potential benefits in that it requires minimal monitoring, exhibits fewer drug 
interactions or dietary interference and has a reduced risk of osteoporosis and heparin-
induced thrombocytopenia compared to other agents.  The therapeutic ranges of optimised 
management have been derived from adult data, however and the rates of major bleeding are 
uncertain (Jones, Newall et al 2011; Monagle, Newall et al 2010). Major bleeding is defined 
as bleeding into a major organ or requiring blood transfusion. Various studies describe rates 
of haemorrhage between 0.2 - 12.2% (Monagle, Newall et al 2010). 
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Optimising the paediatric patient’s clinical management provides additional challenges in 
that drug pharmacokinetics, illness as well as drug and food interactions, contribute to narrow 
therapeutic windows. The frequent non-availability of paediatric drug formulations further 
complicates monitoring and reduces predictability (Monagle, Newall et al 2010). Further 
challenges in therapeutic drug monitoring in children are posed by the regular requirement 
for phlebotomy so that standard laboratory-based investigations can be performed. This is 
compounded by inherently difficult venous access, in addition to relatively large volume of 
blood required to perform the test. Testing methodology is one of the variables that can lead 
to INR instability, with different testing methods using different methods for clot detection, 
different thromboplastin reagents and different sample types (Heneghan, Ward et al 2012).  
Point-of-care (POC) coagulation measurement devices have been developed as a suitable 
alternative. A POC test is performed with a capillary sample placed on a strip, with a test 
result yielded in real time.  This capillary sample is placed on the strip within 30 seconds to 
avoid potential interference with the INR value as a result of tissue-factor release or 
activation of the clotting cascade (Donaldson, Sullivan et al 2010). Plasma or anti-coagulated 
whole blood should not be used. POC devices provide rapid results using finger-prick 
capillary samples (therefore less painful), reduce anxiety for patients and parents, and 
encourage better patient adherence (Moon, Jeong et al 2010). POC devices are already in use 
for home-based self-management in Europe and Australia with patients describing higher 
quality of life and satisfaction with therapy (Bauman, Bruce et al 2013) Bauman et al have 
described home-based management and self-testing programs where TTR was 83% (Bauman, 
Bruce et al 2013). 
Studies comparing the accuracy of POC devices to that of laboratory methods have been 
conducted. Collela et al found that the CoaguCheck XS (Roche Diagnostics) POC device 
underestimated the INR results by only 0.08u (p<0.0001) (Tomiyama 2012). This evidence is 
supported by other studies that have found a non-significant variability between POC devices 
and laboratory tests when the target range is 2-3, further validating the suitability of POC 
devices for outpatient/ home-based care. The authors advised caution when INR values are 
greater than 3.5. In such cases a confirmatory laboratory-based INR should be performed 
(Hill, Perreault et al 2007) (Kong, Lim 2008).  
Lawrie et al however found that CoaguCheck XS INRs between 4.5 - 8 were comparable to 
laboratory INRs (Lawrie, Hills et al 2012). Furthermore, the CoaguCheck XS has been 
validated for use in 4-day old neonates and showed a Spearman correlation coefficient of 
0.967 (p<0.001) (Ijima, Baba et al 2014). The use of POC devices has been extended to use 
in emergency units for adult patients with cerebrovascular disease to help guide treatment 
interventions (Nanduri, Tayal et al 2012) (Beynon, Erk et al 2015). 
Purpose of the Study 
 
There is a growing number of South African children requiring anticoagulation therapy. 
Current outpatient monitoring of oral anticoagulant therapy requires attendance at hospital 
outpatient clinics at regular intervals for standard laboratory-based INR testing.  
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For many of these patients this attendance is a distant and costly trip, and because of the 
inherent delay in treatment adjustments, these patients have to wait hours for test results. This 
results in parents frequently having to take a full day off from work and children missing an 
entire day of school. These factors often restrict monitoring to monthly intervals, limiting 
more frequent testing to ensure a greater TTR.  
Meurer et al recommends that INR should initially be measured daily until stable and then 
gradually increasing intervals to weekly, biweekly and then monthly once therapeutic levels 
are achieved and are stable for at least eight weeks. The interval may need to be reduced in 
patients who are having difficulty in achieving therapeutic INR levels. In the South African 
setting such recommendations are difficult to follow for the abovementioned reasons. More 
frequent testing would be ideal to achieve consistent TTR. 
A validated instrument for POC INR testing in the paediatric population would assist in 
reducing time and costs to both patient and hospital, as well as ensuring effective and 
acceptable health care (Gaw et al 2013). This study aims to validate a POC device against the 
laboratory-based gold standard in the unique setting of Red Cross War Memorial Children’s 
Hospital (RCWMCH), a tertiary paediatric facility. 
Research Question 
 
Is the POC INR monitoring device system suitably accurate in comparison to standard of care 
(SOC) laboratory-based INR measurement for monitoring oral anticoagulation therapy in a 
paediatric population at a tertiary level paediatric hospital? 
 
Aims and Objectives 
 
Aims 
This study aims to determine the accuracy of a portable POC INR monitoring device in 
comparison to the current SOC laboratory measurement method. 
 
Objectives 
1. To describe the accuracy of the INR POC monitoring device compared to the laboratory-
based INR testing in the paediatric population. 
2. To describe the time taken and costs incurred with the INR POC monitoring system 





The study will be conducted at Red Cross War Memorial Children’s Hospital. RCWMCH is 
a tertiary-level hospital that serves as the referral hospital for the paediatric patient population 
of the Western Cape.   
 
Study population  
Children aged between 12 months and 18 years of age (≥12 months to <18 years) presenting 





1. Patients ≥ 12 months to < 18 years of age 
2. Participants will include those on oral anticoagulation for cardiac indications, as well as 
those on oral anticoagulation for other/ non-cardiac indications, regardless of primary 
managing service or diagnosis 
3. Either admitted in hospital or attending the various outpatient clinics at RCWMCH. 
4. Parent/ legal guardian willing and able to provide informed consent 




1. Refusal/inability to consent/ assent 
2. Age less than 12 months or 18 years of age or older 




This study is a prospective observational study. All patients attending RCWMCH who 
require INR testing as per monitoring for oral anticoagulant therapy will be eligible for 
recruitment. 
 
Recruitment and enrolment  
 
Current treatment guidelines call for monthly INR testing in stable patients or more often if 
the INR value is <1.5 or >4. Research participants will be approached to join the study when 
they present for their laboratory-based INR testing at RCWMCH. This may occur in the 
hospital outpatient laboratory, in the various clinics within the hospital or in the inpatient 
setting. Typically, standard of care INR tests are performed by laboratory personnel using 
standard phlebotomy techniques to draw venous blood.  
 
Laboratory personnel will be requested to contact the student investigator when standard of 
care INRs are to be performed. If patients/parents are willing to participate and provide 
informed consent (and assent of the child as appropriate), the student investigator will 
perform the finger prick and collect the sample to be tested with the POC INR device.   
 
The POC sample will be collected within 15 mins of the collection of the venous blood 
sample. More than one sample may be used from the same patient. Clinical decisions will be 
based on the laboratory-based INR results. 
 
Device Information  
 
The Mission 1 PT/INR monitor manufactured by Acon will be used according to the 
manufacturer’s guidelines (Appendix B). This device and associated supplies will be 
provided by the regional Acon representative.   
 
Data Management and Statistical Analysis 
 
Variables of Interest  
Data that will be collected include: 
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• Date and Time of SOC INR sample collection 
• Date and Time of POC INR sample collection 
• Place/ venue of sample collection 
• Gender of patient 
• Date of birth of patient 
• Place of Residence 
• Last recorded weight and date weight taken 
• Indication for INR monitoring 
• Whether or not known CARDIAC patient (i.e. not first INR at RCWMCH) 
• If not known to cardiac service, what is the diagnosis and what is the indication for INR 
monitoring? (text fields) 
• Other chronic co-morbid illnesses 
• Inpatient vs Outpatient status 
• Type, dosage and duration of anticoagulants used in the last 30 days: dosing schedule 
• NHLS laboratory INR value 
• NHLS lab sample receipt time stamp 
• NHLS lab sample result time stamp 
• POC result value 
• POC result date and time 
 
Text field comments will include description of any adverse or unanticipated events that may 
impact data point values. Please refer to data collection form provided in appendices. 
 
Sample Size Calculation 
 
The sample size of paired samples was calculated based on interclass correlation of 5% and 
confidence interval of less than 5% - this value calculated as n=138 paired tests. We will 
express continuous data variables as mean ±SD, percentage or coefficient of variation, as 
appropriate.  
 
Statistical Analysis Plan 
 
We will use the Wilcoxon signed-rank test to compare paired INR values obtained using the 
POC INR and the laboratory method, and Spearman’s rank correlation to correlate the results 
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from the two methods. Finally, the accuracy of POC values will be determined by 
comparison to the INR values from the laboratory method using linear regression analysis.  
 
We will use a Bland-Altman plot to assess the magnitude of disagreement between the 
laboratory INRs and the INRs from the POC method. We will present values with 95% 
confidence intervals. A p-value of 0.05 will be considered significant. Statistical analysis will 
be performed using Stata 15.1 (Statacorp etc). 
Description of Risks and Benefits 
 
The Acon Mission 1 PT/INR monitor device is designed to use fresh capillary whole blood. 
The risks involved in the study are minimal and related to the finger-prick sample collection 
for the POC testing. The drop of blood must be a minimum of 15 microliters. Collection will 
cause minimal discomfort. The standard aseptic technique will be used. The additional 
amount of blood required for the POC testing is therefore minimal and is in line with WHO 
Blood for Research recommendations. 
There will be no direct benefit to the children and families taking part in this study as 
standard laboratory-based results will be used for making clinical decisions. Patients and 
families will be informed of the POC test result. Whether the POC test result is abnormal or 
not, patients will be advised to wait for the laboratory result as per standard of care. 
 
The potential benefit to the larger paediatric population would be the result of the 
recommendation to adopt the INR POC monitoring system – this system is hoped to reduce 
the amount of time and inconvenience required for children and their families who are 
undergoing INR testing and awaiting results-based treatment decisions. 
 
Informed Consent Process 
 
Approval for this study will be obtained from UCT Health Sciences Human Research Ethics 
Committee before any research activities commence. Informed consent will be obtained from 
a parent or legal guardian for participants younger than 18 years of age. Assent will be 
obtained from children between 7 and 17 years of age. Verbal assent will be obtained from 
children aged five to six years. 
 
Patients and their families will be approached for participation while awaiting phlebotomy 
for the INR in the outpatient department laboratory waiting area. In the case of inpatients, 
participants and their families will be approached in the wards.  The informed consent 
process will take place in the private examination rooms or at the patient’s bedside.  
 
Consent forms and patient information leaflets will be made available in English, isiXhosa 
and Afrikaans These consent and assent forms will have been approved by the Ethics 
Committee. The student investigator is fluent in English and Afrikaans. Hospital staff who 
are fluent in isiXhosa will be asked to translate and communicate the informed consent 
document to potential participants and their parents as necessary.  
 
Reimbursement for Participation 
 
There will be no reimbursement to participants or their families for participating in this study. 
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Privacy and Confidentiality 
 
Signed consent, assent and data collection forms will be maintained in a locked office 
environment accessible only to the principal investigator and research support staff in the 
Children’s Heart Disease Research Unit at RCWMCH. 
 
The RedCap database system, supplied and supported by UCT, will be used to record and 
maintain the study data. Access to the system is secure and password protected. All enrolled 
participants will be assigned a study ID number by the RedCap software. A study ID number 
key will be maintained by the PI in a secure and confidential manner. This number will be 
used on the data collection form. 
 
Patient birth date will be collected on the data collection form but will be converted to age at 
the time of collection for data export from RedCap for statistical analysis purposes, so that 
participant confidentiality will be protected. 
 
Emergency care and insurance for research-related injuries 
 




We will apply for Departmental MMed Funds to fund the study. 
 
 
Estimated Project Budget - September 2018 
 
Item Cost Quantity Total 
Printing - CRF, consent form/patient information 
leaflet and assent forms 
    R 1 500 
Digital timer   R 250 
Cotton and strapping tape for 138 patients     R 650 
Consent/Assent translation services      R 1 500 
Statistical Consultation and RedCAP database 
design 
    R 1 500 
Misc Office supplies and sundries     R 600 
        
Total     R 6 000 
    
    
 
   
    
Distribution of findings 
 
This research will be conducted as a minor dissertation in the fulfilment of the degree Master 




Information regarding the outcomes of the study will be shared with RCWMCH Department 
of Paediatrics, local secondary hospitals in the region (i.e. George Regional Hospital etc.) and 
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APPENDIX 2: DATA CAPTURE FORM 
Study ID      __________________________________ 
 









1. Age ≥ 12 months to < 18 years 
2. Presents at RCWMCH for INR testing, regardless of indication or primary managing 
service 
3. Inpatient or attending an outpatient clinic at RCWMCH 
4. Parent/ legal guardian willing and able to provide informed consent 
5. Patient willing and able (appropriate for age) to assent to participation 
 
 Exclusion criteria 
6. Refusal/ inability to consent/ assent 
7. Age less than 12 months or 18 years of age or older 
8. Critically ill/ICU patient 
 
INFORMED CONSENT/ ASSENT 
 




2. Assent given by child?  
a. Yes 
b. No 
c. Verbal (Ages 5 and 6 years) 










2. Date of Birth:    ______________________________ 
(DD/MM/YYYY) 
 
3. Date of Enrolment:     ______________________________ 
(DD/MM/YYYY) 
 
4. Age in months (auto-calculated):  ______________________________ (MMM) 
 




If other, please describe.   ________________________________ (FREE TEXT) 
 
6. Primary Place of Residence: 
• Cape Town Metropole 
• Western Cape (other than Cape Town Metropole) 
• Not from Western Cape 
 
7. Place of Sample Collection  
• Outpatient Clinic 
• Inpatient Ward 
• Ambulatory Medicine department 
• Laboratory phlebotomy department 
• Other 
Specify Other:     ______________________________ (FREE TEXT) 
 
8. Last recorded weight in kilograms:   ______________________________ (XXX.X) 
 
9. Date of last recorded weight:   ________________________ (DD/MM/YYYY) 
 
DISEASE PROFILE/ INDICATION FOR INR TESTING 
 




• Prosthetic Valves 
• Kawasaki Disease 
• Primary Pulmonary Hypertension 




• Liver disease 
• Renal Disease 
• Venous Thromboembolism 
• Arterial Thromboembolism 
• Other non-cardiac indication, describe____________________________________ 
 




• Not Cardiac indication 
 
 If NON-CARDIAC indication, diagnosis?  ______________________________ Free 
Text  
 







• Other, describe concurrent illness  
 ____________________________ (FREE TEXT) 
 
DETAILS OF ANTICOAGULANT THERAPY 





If answered YES to above, type of Anticoagulants used in last 30 days: - May choose more than 
one 
• Warfarin 
• Aspirin  
• Heparin 
• Clexane 
• Other, describe. _________________________________ (FREE TEXT) 
 
 
If Warfarin, Start Date     ______________________________DATE 
(DD/MM/YYYY) 
 
End Date (enter 00 if still on warfarin)  ______________________________DATE 
(DD/MM/YYYY) 
 






If Aspirin, Start Date     ______________________________DATE 
(DD/MM/YYYY) 
 
End Date (enter 00 if still on aspirin)  ______________________________DATE 
(DD/MM/YYYY) 
 
Aspirin Dose      ______________________________NUMBER 
(XX.XX) 
(in milligrams daily) 
 
 
If Heparin, Start Date     ______________________________DATE 
(DD/MM/YYYY) 
 
Heparin End Date (enter 00 if still on heparin) ______________________________DATE 
(DD/MM/YYYY) 
 




If Clexane, Start Date     ______________________________DATE 
(DD/MM/YYYY) 
 
Clexane End Date (enter 00 if still on clexane) ______________________________DATE 
(DD/MM/YYYY) 
 
Clexane Dose      ______________________________NUMBER 
(XX.XXX) 
(in milligrams)   
 
 
Other coagulant, please describe  ______________________________ (FREE TEXT)) 
 
Other Coagulant Start Date    ______________________________DATE 
(DD/MM/YYYY) 
 
Other Coagulant End Date    ______________________________DATE 
(DD/MM/YYYY) 
 
Other Coagulant Dose     ______________________________NUMBER 
(XX.XX) 
 
Specify units     ______________________________ (FREE TEXT)) 
 










Weekly frequency/count (auto-calculated)  ______________________________NUMBER (X.XX) 
 
DETAILS OF SOC/ LABORATORY INR TEST 
 
Date of SOC INR Collection:    _____________________________ (DD/MM/YYYY) 
 
Time of SOC INR Collection:    _____________________________ (HH:MM) 
 
Date of SOC sample receipt    _____________________________DATE 
(DD/MM/YYYY) 
 
Time of SOC sample receipt   _____________________________TIME (HH:MM) 
 
Time of SOC result authorization  _____________________________TIME (HH:MM) 
 
SOC/ Laboratory INR test result   _____________________________NUMBER (XX.XX)
  
 
DETAILS OF POC INR TEST 
 
Date of POC INR Collection:   _____________________________ (DD/MM/YYYY) 
 
Time of POC INR Collection:   _____________________________ (HH:MM) 
 
Time of POC INR result available  _____________________________ (HH:MM) 
 
POC INR test result    _____________________________NUMBER (XX.XX) 
 
ADVERSE EVENTS   
 




AE Description      ______________________________ (FREE TEXT) 
 
OTHER COMMENTS 





APPENDIX 3: Participant information, consent and assent forms (English, Afrikaans, 
isiXhosa) 
 
PARENT/GUARDIAN INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT:  
International Normalised Ratio Monitoring in Children: Comparing the accuracy of portable 
point-of-care monitors to standard of care laboratory monitoring at Red Cross War 
Memorial Children’s Hospital 
 
RESEARCHERS NAME(S): 
Doctor Ryan Moore 
Professor Liesl Zuhlke 
Professor Rik de Decker 
 
ADDRESS:  
Red Cross War Memorial Children’s Hospital, Klipfontein Road, Rondebosch  
UCT Human Research Ethics Committee  - Floor E53, Room 46, Old Main Building, GSH, 
Observatory, 7925 
 
CONTACT NUMBERS:  
Doctor Ryan Moore – 082 867 0176 
Professor Liesl Zuhlke – 076 844 4074 
Professor Rik de Decker – 073 217 6351 
UCT Human Research Ethics Committee – 021 650 3002 
 
We wish to invite your child to take part in a research project – we cannot include your child 
in a research study without your permission (“consent”). Please take some time to read this 
information, which will explain the details of this project. Please ask the study staff or doctor 
any questions about any part of this project that you do not fully understand. It is very 
important that you fully and clearly understand what this research is about and how your 
child could be involved.  
 
Your child’s participation is entirely voluntary, and you are free to say no. If you say no, this 
will not affect your child negatively in any way whatsoever. You are also free to withdraw 
your child from the study at any point, even if you do agree to take par nowt. 
 
This study has been approved by the Human Research Ethics Committee at the University of 
Cape Town and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki (2013), South African Guidelines for Good Clinical 
Practice and Ethics in Health Research: Principles, Processes and Structures (2015). 
 
What is this research study all about? 
Sometimes doctors need to test how well a patient’s blood clots. When people cut 
themselves they normally get a scab, which stops the bleeding. This is called “clotting” of 
blood. Sometimes blood doesn’t clot normally, and this can cause heavy bleeding, so it is 
important to test whether blood clots normally or not. To do this we usually need to take 
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some blood by putting a needle into a vein in the arm, drawing some blood and then 
sending it to the laboratory (“lab”) for clotting tests called the International Normalised 
Ratio or INR.  
 
We want to see if we can do the same INR test without sending blood away to the lab, and by 
just using a small spot of blood taken by pricking a finger. We want to see if the fingerprick 
test is as good as the lab test. The fingerprick test is used in other countries already but it is 
not used much in South Africa. 
 
We will ask other children who are also getting the lab test, and who agree to take part in 
the study, to do the same fingerprick test. We need about 138 children to agree to be in this 
study to get enough results to see if the fingerprick test works as well as the lab test.  
 
Participating in this study should take less than five minutes of you and your child’s time. 
The research part of being in this study is pricking your child’s finger to obtain a drop of 
blood to test on the new device. Your child will still have your blood drawn from a vein in 
his/her arm whether or not you allow your child to be in this study. 
 
If you allow your child to be in this study, we will prick your child’s finger with a tiny needle 
called a lancet. He/she will feel a quick pinch. After the fingerprick we will put on some 
cottonwool to stop any bleeding. The spot of blood from the fingerprick will be tested in a 
machine to get a blood clotting result. 
 
Why have we asked your child to participate? 
We are asking if you will allow your child to take part in our study, because his/her doctor 
has ordered for blood to be taken for lab tests of clotting – the INR test. We will also ask 
other children who are having the same tests if they will take part in the study. 
 
What will happen to your child if he/she takes part? 
The research part of being in this study is pricking your child’s finger to obtain a drop of 
blood to test on the new device. Your child will still have blood drawn from a vein in his/her 
arm whether or not you allow your child to be in this study. 
 
Will your child benefit from taking part in this research? 
There will be no direct benefit to you or your child for participating in this study.  We will 
not use the results of the fingerprick test to make any decisions about your child’s care or 
any changes to his/her medication dose. We are just looking to see if the results we get 
from the POC machine are the same as the results we get from the laboratory results.  
 
The POC device provides INR results within seconds and if this test proves to be as reliable 
as the laboratory-based test - that usually takes about two hours to get results - children in 
the future may have to spend less time at the clinic or hospital to get their INR tested. 
 
Are there in risks involved in your child taking part in this research? 
The risks to your child for being involved in the study are small and are related to the finger-
prick sample collection for the POC testing. The drop of blood must be a minimum of 15 
microliters – a small dot.  
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The finger prick will cause a little pain that will last for a very short time (seconds). We will 
clean the prick spot and use some cottonwool to stop any bleeding. 
 
If you do not agree for your child to take part, what alternatives do they have? 
You don’t have to agree to allow your child to be in this study. Participation is completely 
voluntary. You can say no. If you chose not to allow your child to participate, there will be 
no impact to the medical care your child receives today or in the future. 
 
Who will have access to your child’s medical records? 
Only the researchers and their study team will know your child is in the study. Instead of 
using your child’s name, we will use a code so other people can’t know the information was 
about your child. We might present the results of the study at a conference or publish them 
in a journal, but we would never use your child’s name when we do this.  
 
What will happen in the unlikely event of some form injury occurring as a direct result of 
your taking part in this research study? 
It is very unlikely that your child will experience physical harm if you allow him/her to be in 
this study. If something bad does happen, then your child will be looked after by one of the 
doctors on the study team.  
 
Will you or your child be paid to take part in this study and are there any costs involved? 
You will not be paid for allowing your child to take part in the study. There will also be no 
costs involved for you or your child, if you do allow him/her to take part. 
 
Is there anything else that you should know or do? 
If we ask you to allow your child to provide another sample at another time, we will ask for 
your permission and consent again.  
 
You can contact the Health Research Ethics Committee at tel 021 650 3002 if you have any 
concerns or complaints about the ethical conduct of this study 
 
You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree for my child 
………………………………………………to take part in a research study entitled “International 
Normalised Ratio Monitoring in Children: Comparing the accuracy of portable point-of-care 
monitors to standard of care laboratory monitoring at Red Cross War Memorial Children’s 
Hospital”. 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
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• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that my child’s participation in this study is voluntary and I have not 
been pressurised for my child to take part. 
• I may choose for my child to leave the study at any time and will not be penalised 
or prejudiced in any way. 
• My child may be asked to leave the study before it has finished, if the study doctor 
or researcher feels it is in his/her best interests, or if we do not follow the study 
plan, as agreed to. 
 
 




 ................................................................   .........................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter must 
sign the declaration below. 
 
 




 ................................................................   .........................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa/other. 
 62 
• We encouraged him/her to ask questions and took adequate time to answer 
them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 




 ................................................................   .........................................................  





PARTICIPANT INFORMATION LEAFLET AND ASSENT FORM 
(7-17 years of age) 
   
 
TITLE OF THE RESEARCH PROJECT:  
International Normalised Ratio Monitoring in Children: Comparing the accuracy of 
portable point-of-care monitors to standard of care laboratory monitoring at Red 
Cross War Memorial Children’s Hospital 
 
Monitoring Blood Clotting in Children: Comparing a machine for finger-pricking to the 
laboratory method of checking blood clotting 
 
RESEARCHERS NAME(S): 
Doctor Ryan Moore 
Professor Liesl Zuhlke 
Professor Rik de Dekker 
 
ADDRESS:  
Red Cross War Memorial Children’s Hospital, Klipfontein Road, Rondebosch  
UCT Human Research Ethics Committee  - Floor E53, Room 46, Old Main Building, GSH, 
Observatory, 7925 
 
CONTACT NUMBERS:  
Doctor Ryan Moore – 082 867 0176 
Professor Liesl Zuhlke – 076 844 4074 
Professor Rik de Dekker – 073 217 6351 
UCT Human Research Ethics Committee – 021 650 3002 
 
What is RESEARCH? 
Research is something we do to find out about the way things (and people) work.  We use 
research projects or studies to help us find out more about disease or illness. Research 
also helps us to find better ways of helping children who are sick. 
 
What is this research project all about? 
When people cut themselves they normally get a scab, which stops the bleeding. This is 
called “clotting” of blood. Sometimes blood doesn’t clot normally and this can cause 
children to bleed a lot, so it is important to test whether blood clots normally or not. To 
do this we usually need to take some blood from you by putting a needle into a vein in 
your arm, drawing some blood and sending it to the laboratory (“lab”) for clotting tests 
called the INR.  
 
We want to see if we can do the same INR test without sending blood away to the lab, 
and by just using a small spot of blood taken by pricking a finger. We want to see if the 
fingerprick test is as good as the lab test. The fingerprick test is used in other countries 
already but it is not used much in South Africa. 
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Why have I been invited to take part in this research project? 
We are asking if you will take part in our study, because your doctor has ordered for 
your blood to be taken for lab tests of clotting. We will also ask other children who are 
having the same tests if they will take part in the study. 
 
Who is doing the research? 
I am a doctor who helps look after sick children. I work at Red Cross Children’s Hospital 
here in Cape Town. My boss is Professor Liesl Zuhlke who is a doctor who looks after 
children with heart problems.  
 
What will happen to me in this study? 
Your doctor has asked for a lab INR test to see how your blood clots. This is important, 
and we need to do it even if you say “no” to this study. If you say “yes” to taking part in 
this study, we would like to also do a fingerprick test for blood clotting so we can 
compare the results.  
 
To do this we will prick your finger with a tiny needle called a lancet. You will feel a quick 
pinch. After the fingerprick we will put on some cottonwool to stop any bleeding. The 
spot of blood from the fingerprick will be tested in a machine to get a blood clotting 
result. 
 
We will ask other children who are also getting the lab test, and who agree to take part 
in the study, to do the same fingerprick test. We will put together all the test results at 
the end and see if the fingerprick method is as good as the lab method.  
 
Can anything bad happen to me? 
Nothing bad will happen to you if you say “yes”, except for the small finger prick, which 
may be a bit sore (but it will be very quick). If at any time you feel scared or 
uncomfortable you can tell us and you don’t need to carry on with the test.  
 
Can anything good happen to me? 
If you say “yes” to the fingerprick test, it won’t really help you now, but if we can show 
that this test is as good as the normal lab test it will help other children in the future; 
because the fingerprick test is easier, quicker, and not as painful as normal blood tests.  
 
Will anyone know I am in the study? 
No-one apart from the researchers will know you are in the study. Instead of using your 
name, we will use a code so other people can’t know the information was about you. 
We might present the results of the study or publish them in a journal (a medical 
magazine), but we won’t use your name ever when we do this.  
 
Who can I talk to about the study?  
If you have any questions, you can speak to the researcher who is doing the fingerprick 
test or you can phone any of the numbers given above. 
 
What if I say “no”? 
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You do not need to take part in this research project, even if your parent/guardian says 
that you may. If you change your mind about taking part at any time during the 
research, you can tell your parent/ guardian who can let the researchers know. You will 
not get into trouble and it will not affect the care that your doctor is giving you. 
 
Do you understand this research study and are you willing to take part in it?   
 
YES  NO 
 
Has the researcher answered all your questions? 
 
YES  NO 
 
Do you understand that you can pull out of the study at any time? 
 





_________________________  _____________________  





OUERLIKE/ VOOG INLIGTINGSBLAADJIE EN VERGUNNINGSVORM 
 
TITEL VAN DIE NAVORSINGSPROJEK: 
“International Normalised Ratio” monitering in kinders: vergelykbaarheid van draagbare 
monitors na laboratoriummonitering by Rooikruis Oorlogsgedenk Kinderhospitaal. 
 
NAME VAN NAVORSERS: 
Dokter Ryan Moore 
Professor Liesl Zuhlke 
Professor Rik de Decker 
 
ADRES:  
Rooikruis Oorlogsgedenk Kinderhospitaal, Klipfonteinpad, Rondebosch  
Universiteit van Kaapstad, Komitee vir Menslike Navorskingsetiek - Vloer E53, Kamer 46, Old 
Main Building, GSH, Observatory, 7925 
 
KONTAKNOMMERS:  
Dokter Ryan Moore – 082 867 0176 
Professor Liesl Zuhlke – 076 844 4074 
Professor Rik de Decker – 073 217 6351 
Universiteit van Kaapstad, Komitee vir Menslike Navorskingsetiek – 021 650 3002 
 
Ons will u uitnooi om aan ‘n navorsingsprojek deel te neem - ons kan nie u kind insluit by die 
navorsingsprojek sonder u toestemming nie. Lees gerus die blad deur, hierin word die 
besonderhede van hierdie projek verduidelik. Vra asseblief die navorsingpersoneel of -dokter 
enige vrae wat u ten opsigte van die projek mag hê. Dit is baie belangrik dat u duidelik 
verstaan waaroor hierdie navorsing gaan en hoe u kind betrokke sal wees. 
 
U kind se deelname is heeltemal vrywillig, en u mag weier om u kind te laat deelneem. As u 
weier om u kind te laat deelneem, sal u kind nie op enige manier negatief beïnvloed word nie. 
U is ook vry om u kind te onttrek op enige tydstip, selfs al het u oorspronklik toestemming 
gegee. 
 
Hierdie studie is goedgekeur deur die Komitee vir Menslike Navorskingsetiek by die 
Universiteit van Kaapstad, en sal volgens die etiese riglyne en beginsels van die Internasionale 
Verklaring van Helsinki (2013), Suid-Afrikaanse Riglyne vir Goeie Etiese Praktyk en 
Gesondheidsnarvorsing: Beginsels, Prosesse en Strukture (2015). 
 
Waaroor gaan die navorsing? 
Dokters moet soms toets hoe goed ‘n patient se bloed kan stol. As ‘n men hul self sny, kry hul 
gewoonlik ‘n skurfte, wat die bloeding laat stop. Die proses word “stolling” genoem. Soms 
kan ‘n mens se bloed nie mooi stol om ‘n skurfte te maak nie, en dit kan swaar bloeding 
veroorsaak, so dit is belangrik om te toets of die mens blood normaalweg kan stol of nie. Om 
dit te doen moet ons gewoonlik bloed neem deur om ‘n naald in die arm te sit, die bloed trek 
en dan dit na ‘n laboratorium te stuur vir stollingstoetse - die toets noem ons “International 
Normalised Ratio” of “INR”. 
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Ons wil kyk of ons dieselfde INR-toets kan doen sonder om dit na die laboratorium te stuur, 
en net deur ‘n vingerprik ‘n klein bloedvlek te neem. Ons wil sien of die vingerprik toets net 
so goed soos die laboratoriumtoets is. Die vingerpriktoets word al in ander lande gebruik, 
maar dit word selde in Suid-Afrika gebruik. 
 
Ons sal ander kinders wat ook die laboratoriumtoets kry vra om deel te neem in die studie, 
so- dat hulle ook die vingerpriktoets kan kry. Ons het ongeveer 138 kinders noding om by die 
studie in te stem, sodat ons kan sien of die vingerpriktoets net so goed soos die 
laboratoriumtoets werk. 
 
Dit sal minder as vyf minute neem om aan hierdie studie deel te neem. Die navorsing deel 
van die studie vereis net ‘n prik op u kind se vinger om ‘n druppel bloed te kry sodat ons ‘n 
toets kan doen op die nuwe toestel. Bloed sal steeds van u kind se aar moet geneem word, al 
gee u toestemming of nie. 
 
As u toelaat dat u kind aan hierdie studie deelneem sal ons u kind se vinger met ‘n klein 
naaldjie steek - ons noem die naaldjie ‘n “lanset”. Hy/ sy sal ‘n kleine knypie voel. Na die stekie 
sal ons ‘n stukkie watte by die vinger sit om die bloeding te stop. Die druppeltjie bloed sal dan 
op ‘n masjien geplaas word om ‘n bloedstollings resultaat te kry. 
 
Waarom het ons u gevra om u kind te laat deelneem? 
Ons vra of u u kind sal toelaat om aan ons studie deel te neem, want sy/ haar dokter het 
beveel dat u kind ‘n laboratoriumtoets vir bloedstolling kry - dit is die INR toets. Ons sal ook 
ander kinders vra wat ook die bloedstollingstoets kry om deel te neem. 
 
Wat sal met u kind gebeur as hy/ sy deelneem? 
Die navorsing deel van hierdie studie is om u kind se vinger te steek om ‘n druppel bloed te 
kry om op die nuwe toestel te toets. Bloed sal steeds van u kind se aar moet geneem word, 
al gee u toestemming of nie. 
 
Sal u kind daarby baat vind om aan hierdie navorsing deel te neem? 
Nie u of u kind sal direk voordeel kry uit hierdie studie nie. Ons sal nie die resultaat van die 
vingerpriktoets gebruik om besluite te neem oor sy/haar versorging nie, of om enige 
veranderinge aan sy/ haar medikasie te maak nie. Ons wil net kyk of die resultate van die 
nuwe toestel ooreenstem met die resultate van die laboratoriumtoets. 
 
Die masjientjie verskaf INR-resultate binne sekondes en as hierdie toets blyk om so 
betroubaar te wees as die laboratoriumtoets (wat gewoonlik twee ure neem om resultate te 
verskaf), is dit moontlik dat in die toekoms kinders minder tyd by die kliniek of hospitaal hoef 
te spandeer om hul INR te laat toets. 
 
Is daar risiko’s as my kind deelneem in die navorsing? 
Die risiko vir u kind as gevolg van die studie in klein en is verband aan vingerpriktoets. Die 
bloed druppeltjie is baie klein, en is minstens 15 mikroliter - ‘n klein kolletjie. 
 
Die vingerprik sal ‘n bietjie pyn veroorsaak wat ‘n baie kort tydjie sal duur (sekondes). Ons sal 
die vinger skoon eerste skoonmaak en ons sal watte gebruik om die bloeding te stop. 
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As u nie saamstem dat u kind deelneem nie, watter alternatiewe het u dan? 
U hoef nie saam te stem dat u kind deelneem aan die studie nie. Deelname is heeltemal 
vrywillig - u kan nee sê as u verkies om nie u kind te laat deelneem nie, daar sal geen invloed 
op die mediese sorg van u kind vandag of in die toekoms wees nie. 
 
Wie het toegang tot die mediese rekords van u kind? 
Slegs die navorsers en hul span sal weet dat u kind aan die studie deelneem. In plaas van u 
kind se naam te gebruik, gebruik ons ‘n kode sodat ander mense nie weet van u kind se 
inligting nie. Ons sal moontlik die resultate van die navorsing op ‘n konferensie aanbied of dit 
publiseer in ‘n mediese joernaal, maar ons sal nooit u kind se naam gebruik nie. 
 
Wat sal gebeur in die onwaarskynlike geval dat u kind beseer is as gevolg van die navorsing? 
Dit is onwaarskynlik dat u kind skade sal ly as u toelaat dat hy/sy aan die studie deelneem. As 
daar iets ergs gebeur sal u kind gesorg word deur een van die dokters in die navorsingspan.  
 
Sal u kind betaal word om aan die studie deel te neem en is daar kostes daaraan verbonde? 
U sal nie betaal word om toestemming te gee dat u kind deelneem nie. Daar is ook nie koste 
verbonde aan die studie as u wel toestemming gee nie. 
 
Is daar iets anders wat u moet weet of doen? 
As ons u vra om toe te laat dat ons op ‘n ander tydstip weer ‘n vingerprik doen op u kind sal 
ons weer vir u toestemming vra. 
 
U kan die Komitee vir Gesondheidsnavorsingsetiek skakel by tel 0216503002 indien u enige 
vrae of klagtes het teenoor die etiese gedrag van die studie. 
 
U sal ‘n afskrif van hierdie inligting en toerstemmingsvorm vir u eie rekords ontvang. 
 
Verklaring deur deelnemer 
 
Deur hieronder te teken, gee ek …………………………………..…………. toestemming dat my kind 
………………………………………………mag deelneem aan die studie benoemd “International 
Normalised Ratio” monitering in kinders: vergelykbaarheid van draagbare monitors na 
laboratoriummonitering by Rooikruis Oorlogsgedenk Kinderhospitaal. 
Ek verklaar dat: 
 
• Ek die inligting- en toestemmingsvorm gelees het, of dit was aan my gelees, en 
dat dit in ‘n taal geskryf waarmee ek vlot en gemaklik is. 
• Ek ‘n kans gehad het om vrae te stel en dat al my vrae voldoende beantwoord is. 
• Ek verstaan dat my kind se deelname vrywillig is en dat ek onder geen druk 
geplaas is om my toestemming te gee nie. 
• Ek mag verkies dat my kind of enige tydstip die studie verlaat en hy/sy sal nie 
gepenaliseer word of op enige manier benadeel word nie. 
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• My kind mag gevra word om die studie te verlaat voordat dit afgehandel is, as die 
navorser voel dat dit in sy/ haar beste belang is, of as die studie proses nie gevolg 
word nie, soos ooreengekom. 
 
 




 ................................................................   .........................................................  
Handtekening van deelnemer Handtekening van getuie 
 
 
Verklaring deur ondersoeker 
 
Ek (naam) ……………………………………………..……… verklaar dat: 
 
• Ek die inligting in die dokument aan ………………………………….... verduidelik het. 
• Ek hom/ haar aangemoedig het om vrae te stel en voldoende tyd geneem het om 
dit te beantwoord. 
• Ek is tevrede dat hy/ sy all aspekte van die navorsing voldoende verstaan, soos 
hierbo bespreek. 








 ................................................................   .........................................................  
Handtekening van navorser Handtekening van getuie 
 
 
Verklaring deur tolk 
 
Ek (naam) ……………………………………………..……… verklaar dat: 
 
• Ek die navorser (naam) ………………………………………. gehelp het om die inligting in 
die dokument aan (naam van deelnemer) ……………..…………………………….. te 
verduidelik deur middel van die taal Afrikaans/Xhosa/ander te gebruik. 
• Ek hom/ haar aangemoedig het om vrae te stel en voldoende tyd geneem het om 
dit te beantwoord. 
• EK het die feitlike korrekte weergawe van die inligting oorgegee. 
• Ek is tevrede dat die deelnemer die inhoud van hierdie toestemmings dokument 








 ................................................................   .........................................................  






DEELNEMER INLIGTINGSBLADJIE EN INSTEMMINGSVORM 
(7-17 jaar oud) 
   
TITEL VAN DIE NAVORSINGSPROJEK: 
“International Normalised Ratio” monitering in kinders: vergelykbaarheid van draagbare 
monitors na laboratoriummonitering by Rooikruis Oorlogsgedenk Kinderhospitaal. 
 
Monitering van bloedstolling in kinders: vergelyking van ‘n masjien vir vingerprik met die 
laboratorium metode. 
 
NAME VAN NAVORSERS: 
Dokter Ryan Moore 
Professor Liesl Zuhlke 
Professor Rik de Decker 
 
ADRES:  
Rooikruis Oorlogsgedenk Kinderhospitaal, Klipfonteinpad, Rondebosch  
Universiteit van Kaapstad, Komitee vir Menslike Navorskingsetiek - Vloer E53, Kamer 46, Old 
Main Building, GSH, Observatory, 7925 
 
KONTAKNOMMERS:  
Dokter Ryan Moore – 082 867 0176 
Professor Liesl Zuhlke – 076 844 4074 
Professor Rik de Decker – 073 217 6351 
Universiteit van Kaapstad, Komitee vir Menslike Navorskingsetiek – 021 650 3002 
 
Wat is navorsing? 
Navorsing is iets wat ons doen om uit te vind oor die manier waarop dinge (en mense) werk. 
Ons gebruik navorsingsprojekte of studies om ons te help om meer uit te vind oor siektes. 
Navorsing help ons ook om beter maniere te vind om siek mense te help. 
 
Waaroor gaan hierdie navorsingsprojek? 
As mense hulself sny, kry hulle gewoonlik ‘n skurfte, wat die bloeding laat stop. Dit is 
“bloedstolling” van bloed genoem. Soms stol die bloed nie normaal nie, en dit kan veroorsaak 
dat kinders baie bloei, daarom is dit belangrik om te toets of bloed normaalweg stol of nie. 
Om dit te doen, moet ons gewoonlik ‘n bloedmonster neem deur om ‘n naald in die arm te 
sit om bloed van ‘n aar te neem. Ons stuur dan die bloed na die laboratorium vir ‘n 
bloedstollingstoets wat ons ‘n “INR” noem. 
 
Ons wil kyk of ons dieselfde INR-toets kan doen sonder om bloed na die laboratorium te stuur, 
en net deur ‘n klein druppeltjie bloed te neem deur middel van ‘n vingerprik. Ons wil sien of 
die vingerpriktoets net so goed soos die laboratoriumtoets is. Die vingerprik toets word al 
reeds in ander lande gebruik, maar nie in Suid-Afrika nie. 
 
Waarom is ek uitgenooi om aan hierdie navorsingsprojek deel te neem? 
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Ons vra of u aan ons studie sal deelneem, want u dokter het beveel dat u ‘n laboratoriumtoets 
vir bloedstolling kry - dit is die INR toets. Ons sal ook ander kinders vra  wat ook die 
bloedstollingstoets kry om deel te neem. 
 
Wie doen die navorsing? 
Ek is ‘n dokter wat met siek kinders werk. Ek werk by die Rooikruis-kinderhospitaal hier in 
Kaapstad. My baas is professor Liesl Zuhlke, ‘n dokter wat omsien na kinders met 
hartprobleme. 
 
Wat sal met my in die studie gebeur? 
U dokter het gevra vir ‘n laboratorium INR-toets om te sien hoe jou bloed stol. Dit is belangrik, 
en ons moet dit, selfs al sê u “nee” vir hierdie studie. As u “ja” sêom deel te neem wil ons ook 
‘n vingerprik toets vir bloedstolling neem sodat ons die resultate vir albei toetse kan vergelyk. 
 
Om dit te doen, sal ons u vinger steek met ‘n klein naald wat ons ‘n “lanset” noem. U sal ‘n 
vinnige knypie voel. Na die vingerprik gebruik ons ‘n stukkie watte om bloeding te voorkom. 
Die bloed druppeltjie van die vingerprik sal in ‘n masjien getoets word om bloedstolling 
resultaat te kry. 
 
Ons sal ander kinders wat ook die laboratoriumtoets kry vra om deel te neem, om dieselfde 
vingerprik toets te kry. Ons sal al die toetsresultate aan die einde opstel en kyk of die 
vingerprik metode net so goed soos die laboratorium metode is. 
 
Kan iets sleg met my gebeur? 
Niks sleg kan met jou gebeur as jy “ja” sê nie, behalwe vir ‘n klein vingerprik wat ‘n bietjie seer 
kan wees, maar baie vinnig sal wees. As u op enige tydstip bang of ongemaklik voel, kan u ons 
sê en dan hoef ons nie met die vingerprik  toets voort te gaan nie. 
 
Kan iets goeds met my gebeur? 
As u “ja” sê vir die vingerprik toets, sal dit nie onmiddellik vir u baat vind nie, maar as die 
studie kan wys dat die vingerprik toets net so goed soos die laboratorium toets is, dan kan 
ons kinders in die toekoms help; omdat die vingerprik toets makliker, vinniger en minder 
pynlik is as die laboratorium toets. 
 
Sal enigiemand weet dat ek aan die studie deelneem? 
Niemand anders as die navorsers sal weet dat u aan die studie deelneem nie. In plaas van u 
naam te neem, sal ons ‘n kode gebruik sodat ander mense nie kan weet dat die inligting aan 
u behoort nie. Ons mag dalk die studie se resultate op ‘n mediese joernaal of tydskrif 
publiseer, maar ons sal nooit u naam gebruik nie. 
 
Met wie mag ek oor die studie praat? 
As u vrae het, kan u met die navorser wat die vingerprik toets doen praat, of u kan enige van 
die bogenoemde nommers skakel. 
 
Wat as ek “nee” sê? 
U hoef nie aan die navorsingsprojek deel te neem nie, al sê u ouer/ voog dat jy mag. As u later 
besluit om nie deel te neem nie, kan u vir u ouer/ voog sê, sodat hulle vir die navorser kan 
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vertel. Jy sal nie in die moeilikheid beland nie, en die sal nie die versorging wat u dokter aan 
u gee beïnvloed nie. 
 
Verstaan u hierdie navorsing en is u bereid om daaraan deel te neem? 
 
  JA  NEE 
 
Het die navorser al u vrae beantwoord? 
 
  JA  NEE 
 
Verstaan u dat u enige tyd by die studie kan onttrek? 
 





_________________________  _____________________  








UMXHOLO WEPROJEKTHI YOPHANDO:  
Umlinganiselo Oqhelekileyo Wehlabathi Ohlolayo Ebantwaneni: Uthelekisa ukuchana 
kweepoyinti ezibanjwayo ezinyamekelayo nezihlolayo elabhorathri e-Red Cross War 
Memorial Children’s Hospital 
 
IGAMA (AMAGAMA) LOMPHANDI: 
UGqirha Ryan Moore 
UProfesa Liesl Zuhlke 
UProfesa Rik de Decker 
 
ADRESI:  
Red Cross War Memorial Children’s Hospital, Klipfontein Road, Rondebosch  
IKomiti Yabantu Yophando Yokuziphatha Yase-UCT  - Floor E53, Room 46, Old Main Building, 
GSH, Observatory, 7925 
 
IINOMBOLO ZONXIBELELWANO:  
UGqirha Ryan Moore – 082 867 0176 
UProfesa Liesl Zuhlke – 076 844 4074 
UProfesa Rik de Decker – 073 217 6351 
IKomiti Yabantu Yophando Yokuziphatha Yase-UCT – 021 650 3002 
 
Sithanda ukumema umntwana wakho ukuba athathe inxaxheba kwiprojekthi yophando – 
asikwazi ukuquka umntwana wakho kuphando lophononongo ngaphandle kwemvume yakho 
(“nikela imvume”). Nceda uziphe ixesha lokufunda le nkcazelo, eza kuchaza iinkcukacha zale 
projekthi. Nceda ubuze abasebenzi okanye ugqirha wophononongo nayiphi na imibuzo 
ephathelele nayiphi na inxalenye yale projekthi ongayiqondi ngokupheleleyo. Kubalulekile 
ukuba uqonde ngokupheleleyo nangokucacileyo oko kuqulethwe lolu phando kunye nendlela 
umntwana wakho anokubandakanyeka ngayo.  
 
Ukuthatha inxaxheba komntwana wakho kokokuzithandela ngokupheleleyo, yaye 
ukhululekile ukuthi hayi. Ukuba uthi hayi, oku akuzokuchaphazela umntwana wakho kakubi 
nangayiphi na indlela. Ukhululekile ukurhoxisa umntwana wakho kolu phononongo 
nangaliphi na ixesha, kwanokuba uyavuma ukuthatha inxaxheba ngoku. 
 
Olu phononongo luye lwagunyaziswa yiKomiti Yabantu Yophando Yokuziphatha 
kwiYunivesithi yaseKapa yaye luza kuqhutywa ngokuphathelele indlela yemiyalelo nemigaqo 
yokuziphatha yehlabathi Yokwazisa ye-Helsinki (2013), Imiyalelo YoMzantsi Afrika 
yoQheliselo Lweyeza Elungileyo kunye Nokuziphatha Kuphando Lwempilo: Imigaqo, 
Iinkqubo kunye Nobume (2015). 
 
Lungantoni olu phononongo? 
Maxa wambi, oogqirha kufuneka bavavanye indlela igazi lesigulane eliba lihlwili ngayo. Xa 
abantu bezisika ngokuqhelekileyo bafumana uqweqwe, nto leyo enqanda ukopha. Oku 
kubizwa ngokuba “lihlwili” legazi. Maxa wambi, ngokuqhelekileyo igazi alibi lihlwili, yaye 
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oku kusenokubangela ukopha kakhulu, kubalulekile ukuvavanya enoba igazi liba lihlwili 
ngendlela eqhelekileyo okanye akunjalo. Ukuze wenze oku, ngokuqhelekileyo kufuneka 
sithathe igazi elithile ngokufaka inaliti kumthambo wengalo, sitsale igazi size emva koko 
silithumele elebhorathri (“lebhu”) livavanyelwe ukuba lihlwili nto leyo ebizwa ngokuba 
nguMlinganiselo Oqhelekileyo Wehlabathi okanye i-INR.  
 
Sifuna ukubona enoba singenza uvavanyo olufanayo lwe-INR ngaphandle kokuthumela igazi 
elebhu, yaye nangokusebenzisa nje ichaphaza legazi elithathwe ngokuhlaba umnwe. Sifuna 
ukubona enoba uvavanyo lokuhlaba umnwe lulungile kusini na njengovavanyo lwaselebhu. 
Uvavanyo lokuhlala umnwe sithetha nje luyasetyenziswa kwamanye amazwe kodwa 
alukasetyenziswa kakhulu eMzantsi Afrika. 
 
Siza kucela abanye abantwana abafumana uvavanyo olufanayo lwaselebhu, yaye abaye 
bavuma ukuthatha inxaxheba kuphononongo, ukuze benze uvavanyo olufanayo lokuhlaba 
umnwe. Sifuna malunga nabantwana abali-138 abaza kuvuma ukuba kolu phononongo 
ukuze sifumane iziphumo ezaneleyo ukuba uvavanyo lokuhlaba umnwe luyasebenza 
ngokunjalo nangovavanyo lwaselebhu.  
 
Ukuthatha inxaxheba kolu phononongo kufanele kuthathe ngaphantsi kwemizuzu emihlanu 
yexesha lakho kunye nelomntwana wakho. Inxalenye yophando yokuba kolu phononongo 
kukuhlaba umnwe womntwana wakho ukuze sifumane icontsi legazi silivavanye kwidivayisi 
entsha. Umntwana wakho sekunjalo uza kuba negazi elitsalwe kumthambo wengalo yakhe 
enoba uyamvumela okanye akumvumeli umntwana wakho ukuba abe kolu phononongo. 
 
Ukuba uyamvumela umntwana wakho ukuba abe kolu phononongo, siza kuhlaba umnwe 
womntwana wakho ngenaliti encinane ebizwa ngokuba yi-lancet. Uza kuva ukuhlatywa 
okukhawulezileyo. Ngemva kokuhlatywa emnweni siza kubeka i-cottonwool ukuze sinqande 
nakuphi na ukopha. Ichaphaza legazi elisemnweni liza kuvavanywa kumatshini ukuze 
sifumane imiphumo yokuba lihlwili. 
 
Kutheni siye sacela umntwana wakho ukuba abe nenxaxheba? 
Siyabuza enoba uza kuvumela umntwana wakho abe nenxaxheba kuphononongo lwethu, 
kuba ugqirha wakhe uye wayalela ukuba igazi lithathwe ukuze liyovavanyelwa ihlwili elebhu 
– uvavanyo lwe-INR. Kwakhona, siza kucela abanye abantwana abaye baba novavanyo 
olufanayo enova baza kuthatha inxaxheba kusini na kuphononongo. 
 
Kuza kwenzeka ntoni kumntwana wakho ukuba uthatha inxaxheba? 
Inxalenye yophando yokuba kolu phononongo kukuhlaba umnwe womntwana wakho ukuze 
sifumane ichaphaza legazi eliza kuvavanywa kwidivayisi entsha. Sekunjalo umntwana wakho 
uza kutsalwa igazi emthanjeni wengalo yakhe enoba uyamvumela okanye akumvumeli 
umntwana wakho ukuba abe kolu phononongo. 
 
Ngaba umntwana wakho uza kuzuza ngokuthatha inxaxheba kolu phononongo? 
Ayikho inzuzo engqalileyo oza kuyifumana okanye umntwana wakho ngokuthatha inxaxheba 
kolu phononongo. Asiyi kuzisebenzisa iziphumo zovavanyo zokuhlatywa komnwe ukuze 
senze naziphi na izigqibo ngokuphathelele ukunyamekelwa komntwana wakho okanye 
naluphi na utshintsho kwithamo leyeza lakhe. Sifuna ukubona enoba imiphumo 
esiyifumanayo kumatshini we-POC iyafana neziphumo esizifumana kwiziphumo zaselebhu.  
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Idivayisi ye-POC inikela iziphumo ze-INR ngemizuzwa nje yaye ukuba olu vavanyo lungqina 
ukuba lunokuthenjwa njengovavanyo olwenziwe elebhu – ngokuqhelekileyo oko kuthatha 
malunga neeyure ezimbini ukuze kufunyanwe iziphumo – abantwana kwixesha elizayo 
basenokuchitha ixesha elincinane ekliniki okanye esibhedlele ukuze bafumane uvavanyo 
lwabo lwe-INR. 
 
Ngaba ikho imingcipheko ebandakanyekileyo kumntwana wakho ngokuthatha inxaxheba 
kolu phononongo? 
Imingcipheko kumntwana wakho ngokuthatha inxaxheba kuphononongo incinane yaye 
inxulumene nesampulu yokuhlatywa komnwe eqokelelelwe uvavanyo lwe-POC. Icontsi 
legazi limele libe ubuncinane ne-15 le-microliters – ichaphaza elincinane.  
 
Ukuhlatywa emnweni kuza kubangela intlungu encinane eza kuthatha ixesha elifutshane 
(imizuzwana). Siza kuyicoca indawo ekuhlatywe kuyo size sisebenzise i-cottonwool ukuze 
sinqande nakuphi na ukopha. 
 
Ukuba awuvumi ukuba umntwana wakho athathe inxaxheba, yeyiphi enye into abanayo? 
Akunyanzelekanga uvume ukuze umntwana wakho abe kolu phononongo. Ukuthatha 
inxaxheba kokokuzithandela ngokupheleleyo. Usenokuthi hayi. Ukuba ukhetha 
ukungamvumeli umntwana wakho ukuba abe nenxaxheba, oko akuyi kuchanaba 
ukunyamekelwa komntwana wakho kunyango alufumanayo namhlanje okanye kwixesha 
elizayo. 
 
Ngubani oza kuhlola iingxelo zonyango zomntwana wakho? 
Ngabaphandi neqela labo lophononongo kuphela abaza kwazi ukuba umntwana wakho 
ukuphononongo. Kunokuba sisebenzise igama lomntwana wakho, siza kusebenzisa 
ikhowudi ukuze abanye abantu bangazi inkcazelo ukuba ibingeyomntwna wakho. 
Sinenokubonisa iziphumo zophononongo kwingqungquthela okanye sizipapashe kwijenali, 
kodwa asisoze sisebenzise igama lomntwana wakho xa sisenza oku.  
 
Kuza kwenzeka ntoni kwimeko apho ngandlela ithile kwenzeka ukulimala ngenxa 
yokuthatha inxalenye ngokungqalileyo kolu phando lophononongo? 
Akunakwenzeka tu ukuba umntwana wakho onzakale emzimbeni ukuba uyamvumela abe 
kolu phononongo. Ukuba kwenzeka into embi, ngoko ke, umntwana wakho uya 
kunyamekelwa ngomnye wogqirha abakwiqela lophononongo.  
 
Ngana wena okanye umntwana wakho niza kuhlawulwa ngokuthatha inxaxheba kolu 
phononongo yaye zikhona naziphi na iindleko ezibandakanyekileyo? 
Awuyi kuhlawulwa ngokuvumela umntwana wakho ukuba athathe inxaxheba kuphononongo. 
Kwakhona, akuyi kubakho zindleko zibandakanyekileyo zakho okanye zomntwana wakho, 
ukuba uyamvumela ukuba athathe inxaxheba. 
 
Ngaba ikho enye into ofanele uyazi okanye uyenze? 
Ukuba siyakucela ukuba uvumele umntwana wakho ukuba anikele ngenye isampulu ngelinye 
ixesha, siza kucela imvume yakho yaye nephepha elinikela imvume kwakhona.  
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Unokuqhagamshela iKomiti Yophando Yokuziphatha Yempilo apha kule nombolo 021 650 
3002 ukuba unazo naziphi na izinto ezikukhathazayo okanye izikhalazo ngokuphathelele 
indlela yokuziphatha yolu phononongo 
 
Uza kufumana ikopi yale nkcazelo kunye nefomu enikela imvume ukuze uzigcinele yona 
kwiingxelo zakho. 
 
Ukuvuma ngumthathi nxaxheba 
 
Ngokutyobela ngezantsi, Mna …………………………………..…………. ndiyavuma ukuba umntwana wam 
………………………………………………ukuba athathe inxaxheba kuphando lophononongo olubizwa 
ngokuba “Umlinganiselo Oqhelekileyo Wehlabathi Ohlolayo Ebantwaneni: Uthelekisa 
ukuchana kweepoyinti ezibanjwayo ezinyamekelayo nezihlolayo elabhorathri e-Red Cross 
War Memorial Children’s Hospital”. 
Ndiyavuma ukuba: 
 
• Ndiye ndafunda okanye ndiyifundelwe le nkcazelo nefomu enikela imvume yaye 
ibhalwe ngolwimi endityibilika nendikhululeke ngalo. 
• Ndiye ndaba nethuba lokubuza imibuzo yaye yonke imibuzo yam iye yaphendulwa 
ngokufanelekileyo. 
• Ndiyaqonda ukuba umntwana wam ngokuthatha inxaxheba kolu phononongo 
uyazithandela yaye andikhange ndicinezelwe ukuba umntwana wam athathe 
inxaxheba. 
• Ndisenokukhetha ukuba umntwana wam alushiye uphononongo nangaliphi na 
ixesha yaye andiyi kuhlawuliswa okanye ndicalulwe nangayiphi na indlela. 
• Umntwana wam unokucelwa ukuba alushiye uphononongo ngaphambi kokuba 
luphele, ukuba ugqirha wophononongo okanye umphandi uvakalelwa ukuba kuza 








 ................................................................   .........................................................  





Mna (igama) ……………………………………………..……… ndiyavuma ukuba: 
 
• Ndiye ndayicacisa inkcazelo ekwelu xwebhu ku………………………………….. 
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• Ndiye ndamkhuthaza ukuba abuze imibuzo yaye ndiye ndazipha ixesha elaneleyo 
ukuze ndimphendule yona. 
• Ndanelisekile kukuba eye waqonda ngokwaneleyo zonke iinkalo zophando, 
njengoko ziye zaxutyushwa ngasentla 
• Ndisebenzise/andikhange ndisebenzise umguquleli.  (Ukuba kuye kwasetyenziswa 
umguquleli, ngoko ke, umguquleli kumele atyobele uvumo olusezantsi. 
 
 




 ................................................................   .........................................................  





Mna (igama) ……………………………………………..……… ndiyavuma ukuba: 
 
• Ndiye ndanceda umphandi (igama) ………………………………………. Ukuze acacisele 
inkcazelo ekweli xwebhu (igama lomthathi nxaxheba) 
u……………..…………………………….. esebenzisa ulwimi lwe-
Afrikansi/isiXhosa/nolunye. 
• Siye samkhuthaza ukuba abuze imibuzo saza sazipha ixesha elaneleyo ukuze 
simphendule yona. 
• Ndiye ndadlulisela ingxelo echanileyo yoko endiye ndakuxelelwa. 
• Ndanelisekile kuba umthathi nxaxheba eye waqonda ngokupheleleyo 
okuqulethwe lolu xwebhu olwazisa ngokunikela imvume yaye uye 
waphendulelwa yonke imibuzo yakhe ngokwaneleyo. 
 
 




 ................................................................   .........................................................  





IPHEPHA LENKCAZELO LOMTHATHI NXAXHEBA NEFOMU ENIKELA 
IMVUME 
(7-17 iminyaka ubudala) 
   
 
UMXHOLO WEPROJEKTHI YOPHANDO:  
Umlinganiselo Oqhelekileyo Wehlabathi Ohlolayo Ebantwaneni: Ukuthelekisa 
ukuchana kweepoyinti ezibanjwayo zokunyamekela ezihlolayo ukusa kwimilinganiselo 
yokunyamekela elabhorathri ehlolayo e-Red Cross War Memorial Children’s Hospital 
 
Ukuhlolisisa Ihlwili Kwigazi eBantwaneni: Ukuthelekisa umatshini nokuhlatywa 
ngokucofoza ukusa kwindlela yaselabhorathri yokujonga ukuba lihlwili 
 
IGAMA (AMAGAMA) LOMPHANDI: 
UGqirha Ryan Moore 
UProfesa Liesl Zuhlke 
UProfesa Rik de Dekker 
 
ADRESI:  
Red Cross War Memorial Children’s Hospital, Klipfontein Road, Rondebosch  
IKomiti Yabantu Yophando Yokuziphatha Yase-UCT  - Floor E53, Room 46, Old Main 
Building, GSH, Observatory, 7925 
 
IINOMBOLO ZOQHAGAMSHELWANO:  
UGqirha Ryan Moore – 082 867 0176 
UProfesa Liesl Zuhlke – 076 844 4074 
UProfesa Rik de Dekker – 073 217 6351 
IKomiti Yabantu Yophando Yokuziphatha Yase-UCT – 021 650 3002 
 
Yintoni uPHANDO? 
Uphando yinto esiyenzayo ukuze sifumanise ngendlela izinto (kunye namabantu) 
abasebenza ngayo.  Sisebenzisa iiprojekthi zophando okanye izifundo ukuze zisincede 
sifumanise okungakumbi ngokuphathelele izifo okanye ukugula. Uphando lukwasinceda 
sifumane iindlela ezibhetele zokunceda abantwana abagulayo. 
 
Lungantoni uphando lweprojekthi? 
Xa abantu bezisika ngokuqhelekileyo bafumana uqweqwe, nto leyo enqanda ukopha. Oku 
kubizwa ngokuba “lihlwili” legazi. Maxa wambi, ngokuqhelekileyo igazi alibi lihlwili, 
yaye oku kunokubangela ukopha kakhulu ebantwaneni, ngoko kubalulekile ukuvavanya 
enoba igazi liba lihlwili ngendlela eqhelekileyo okanye akunjalo. Ukuze senze oku, 
ngokuqhelekileyo kufuneka sithathe igazi elithile kuwe ngokufaka inaliti kumthambo 
wengalo yakho, sitsale igazi size emva koko silithumele elebhorathri (“lebhu”) 
livavanyelwe ukuba lihlwili nto leyo ebizwa ngokuba yi-INR.  
 
Sifuna ukubona enoba sinokwenza okufanayo kuvavanyo lwe-INR ngaphandle 
kokuthumela igazi elebhu, yaye nokusebenzisa nje ichaphaza elincinane legazi 
ngokuhlaba umnwe. Sifuna ukubona enoba uvavanyo lokuhlaba umnwe lulunge 
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njengovavanyo lwaselebhu kusini na. Uvavanyo lokuhlaba umnwe lusetyenziswa 
kwamanye amazwe sithetha nje kodwa alusetyenziswa eMzantsi Afrika. 
 
Kutheni ndiye ndamenywa ukuze ndithathe inxaxheba kule projekthi yophando? 
Siyabuza enoba ungakwazi ukuthatha inxaxheba kuphononongo lwethu, kuba ugqirha 
wakho uye wayalela ukuba igazi lakho lisiwe elebhu ukuze livavanyelwe ihlwili. 
Kwakhona, siza kubuza abanye abantwana abafumana uvavanyo olufanayo enoba baza 
kuthatha inxaxheba kolu phononongo kusini na. 
 
Ngubani owenza uphando? 
Ndingugqirha onceda ekunyamekeleni abantwana abagulayo. Ndisebenza kwisiBhedlele 
Sabantwana se-Red Cross apha eKapa. Ibhosi yam nguProfesa Liesl Zuhlke ongugqirha 
onyamekela abantwana abaneengxaki zentliziyo.  
 
Kuza kwenzeka ntoni kum kolu phononongo? 
Ugqirha wakho uye wacela uvavanyo lwaselebhu lwe-INR ukuze abone enoba igazi lakho 
liba namahlwili. Oku kubalulekile, yaye kufuneka sikwenze kwanokuba uthi “hayi” kolu 
phononongo. Ukuba uthi “ewe” ukuthatha inxaxheba kolu phononongo, singathanda 
ukwenza uvavanyo lehlwili legazi ngokuhlaba emnweni ukuze sithelekise iziphumo.  
 
Ukuze senze oku siza kuhlaba umnwe wakho ngenaliti encinane ebizwa ngokuba yi-
lancet. Uza kuva ukuhlatywa okukhawulezileyo. Ngemva kokuhlatywa emnweni siza 
kubeka i-cottonwool ukuze sinqande nakuphi na ukopha. Ichaphaza legazi elisemnweni 
liza kuvavanywa kumatshini ukuze sifumane imiphumo yokuba lihlwili. 
 
Siza kubuza abanye abantwana abakwafumana uvavanyo lwaselebhu, yaye abavumayo 
ukuthatha inxaxheba kuphononongo, ukuze nabo benze uvavanyo lokuhlaba umnwe 
olufanayo. Siza kubeka kunye zonke iziphumo zovavanyo ekugqibeleni size sibone enoba 
indlela yokuhlaba umnwe ilunge ngokufana nendlela yaselebhu.  
 
Ngaba ikho into embi enokwenzeka kum? 
Ayikho into embi eza kwenzeka kuwe ukuba uthi “ewe”, ngaphandle kokuhlatywa 
komnwe okuncinane, mhlawumbi esenokuba buhlungu kancinane (kodwa oku kuza 
kwenzeka ngokukhawuleza). Ukuba nangaliphi na ixesha uziva usoyika okanye 
awukhululekanga, unokusixelela yaye akuyomfuneko ukuqhubeka novavanyo.  
 
Ngaba ikho into entle enokwenzeka kum? 
Ukuba uthi “ewe” kuvavanyo lokuhlatywa emnweni, oko akuzokukunceda ngoku kodwa 
ukuba singabonisa ukuba olu vavanyo lulunge ngendlela efanayo kunovavanyo 
oluqhelekileyo lwaselebhu kuza kunceda abanye abantwana kwixesha elizayo; kuba 
uvavanyo lukuhlaba emnweneni lulula, luyakhawuleza, yaye alukho buhlungu 
kunovavanyo oluqhelekileyo lwegazi.  
 
Ngaba ukho umntu oza kwazi ukuba ndikuphononongo? 
Akekho umntu ngaphandle kwabaphandi oya kukwazi ukuba ukuphononongo. Kunokuba 
sisebenzise igama lakho, siza kusebenzisa ikhowudi ukuze abanye abantu bangayazi 
inkcazelo ukuba ibingawe. Sisenokubonisa iziphumo zophononongo okanye sizipapashe 
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kwijenali (imagazini yezonyango), kodwa asisoze sisebenzise igama lakho nanini na xa 
sisenza oku.  
 
Ndinokuthetha nabani ngokuphathelele uphononongo?  
Ukuba unayo nayiphi na imibuzo, unokuthetha nomphandi owenza uvavanyo lokuhlaba 
umnwe okanye unokufowunela naziphi na iinombolo ezinikelwe ngasentla. 
 
Kuthekani ukuba ndithi “hayi”? 
Akuyomfuneko ukuba ube yinxalenye kule projekthi yophando, kwanokuba 
umzali/umnakekeli wakho uthi ufanele wenjenjalo. Ukuba utshintsha ingqondo yakho 
ngokuphathelele ukuthatha inxaxheba nangaliphi na ixesha ebudeni bophando, 
unokuxelela umzali/ umnakekeli wakho onokwazisa abaphandi. Awuyi kuba sengxakini 
yaye oku akuyi kuchaphazela ukunyamekelwa kwakho ngugqirha wakho. 
 
Ngaba uyaluqonda olu phando lophononongo yaye ukulungele ukuthatha inxaxheba 
kulo?   
 
EWE  HAYI 
 
Ngaba umphandi uye waphendula yonke imibuzo yakho? 
 
EWE  HAYI 
 
Ngaba uyaqonda ukuba unokuyeka kolu phononongo nangaliphi na ixesha? 
 





_________________________  _____________________  
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APPENDIX 6: INSTRUCTIONS TO AUTHORS (SAMJ) 
Author Guidelines 
The SAMJ has launched a new submission and tracking system. Authors will be required to 
register a profile on the Editorial Manager platform in order to submit a manuscript.  
To submit a manuscript, please proceed to the SAMJ Editorial Manager website:  
www.editorialmanager.com/samj 
To access and submit an article already in production, please see the guidelines here. 
Author Guidelines 
Please view the Author Tutorial for guidance on how to submit on Editorial Manager. 
Please take the time to familiarise yourself with the policies and processes below. If you still 
have any questions, please do not hesitate to ask our editorial staff (tel.: +27 (0)21 532 1281, 
email: submissions@hmpg.co.za). 
 SAMJ policies 
• Types of articles considered by the SAMJ
• Article Processing Charges
• Authorship
• Conflict of interest
• Research ethics committee approval
• Clinical trials






• Preparing an article for anonymous review
• General article format/layout




From submission to acceptance
• Submission and peer-review
• Production process
• Changing contact details or authorship
Publication
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• Online versus print 
• Errata and retractions 
• Indexing 
SAMJ Policies 
Type of articles considered by the SAMJ 
The SAMJ will no longer limit the articles accepted to those that have ‘general medical 
content’, but is intending to capture the spectrum of medical and health sciences, grouped 
by relevance to the country’s burdens of disease. This content will include research in the 
social sciences and economics that is relevant to the medical issues around our burden of 
disease. Please see ‘A new vision for the SAMJ – and a call for papers’ for a full discussion 
of the new directions for the SAMJ. 
We accept the following types of articles: 
• Research 
• Reviews 
• Clinical trials 
• Editorials 




• Book reviews 
• Ad hoc supplements e.g. guidelines, 
conference/congress abstracts, Festschrifts* 
  
 
The following articles are by invitation only: 
• Guest editorial 
• Continuing Medical Education (CME) 
 
*Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
  
Publication Fees  
All articles published in the South African Medical Journal are open access and freely 
available online upon publication. This is made possible by applying a business model to 
offset the costs of peer review management, copyediting, design and 
production, by charging a publication fee of R5 565 (ex vat) for each research article 
published. The charge applies only to Research articles submitted after 1 March 2017. The 
publication fee is standard and does not vary based on length, colour, figures, or other 
elements. 
 
When submitting a Research article to the SAMJ, the submitting author must agree to pay 
the publication fee should the article be accepted for publication. The publicaiton fee is 
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payable when your manuscript is editorially accepted and before production commences for 
publication. The submitting author will be notified that payment is due and given details on 
the available methods of payment. Prompt payment is advised; the article will not enter into 
production until payment is received. 
Queries can be directed to claudian@hmpg.co.za. 
 
Please refer to the section on ‘Sponsored Supplements’ regarding the publication of 
supplements, where a charge is applicable. Queries can be directed to dianes@hmpg.co.za 
or claudian@hmpg.co.za 
Authorship 
Named authors must consent to publication. Authorship should be based on: (i) substantial 
contribution to conceptualisation, design, analysis and interpretation of data; (ii) drafting or 
critical revision of important scientific content; or (iii) approval of the version to be 
published. These conditions must all be met (uniform requirements for manuscripts 
submitted to biomedical journals; refer to www.icmje.org) 
  
If authors’ names are added or deleted after submission of an article, or the order of the 
names is changed, all authors must agree to this in writing. 
  
Please note that co-authors will be requested to verify their contribution upon submission. 
Non-verification may lead to delays in the processing of submissions. 
Author contributions should be listed/described in the manuscript. 
  
Conflicts of interest 
Conflicts of interest can derive from any kind of relationship or association that may 
influence authors’ or reviewers’ opinions about the subject matter of a paper. The existence 
of a conflict – whether actual, perceived or potential – does not preclude publication of an 
article. However, we aim to ensure that, in such cases, readers have all the information they 
need to enable them to make an informed assessment about a publication’s message and 
conclusions. We require that both authors and reviewers declare all sources of support for 
their research, any personal or financial relationships (including honoraria, speaking fees, 
gifts received, etc) with relevant individuals or organisations connected to the topic of the 
paper, and any association with a product or subject that may constitute a real, perceived or 
potential conflict of interest. If you are unsure whether a specific relationship constitutes a 
conflict, please contact the editorial team for advice. If a conflict remains undisclosed and is 
later brought to the attention of the editorial team, it will be considered a serious issue 
prompting an investigation with the possibility of retraction. 
  
Research ethics committee approval 
Authors must provide evidence of Research Ethics Committee approval of the research 
where relevant. Ensure the correct, full ethics committee name and reference number is 
included in the manuscript. 
If the study was carried out using data from provincial healthcare facilities, or required 
active data collection through facility visits or staff interviews, approval should be sought 
from the relevant provincial authorities. For South African authors, please refer to the 
guidelines for submission to the National Health Research Database. Research involving 
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human subjects must be conducted according to the principles outlined in the Declaration of 
Helsinki. Please refer to the National Department of Health’s guideline on Ethics in Health 
research: principles, processes and structuresto ensure that the appropriate requirements 
for conducting research have been met, and that the HPCSA’s General Ethical Guidelines 
for Health Researchers have been adhered to. 
  
Clinical trials 
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should 
be registered with the appropriate national clinical trial registry (or any international 
primary register, if relevant), and the trial registration number should be cited at the end of 
the abstract. All clinical trial reports must also contain a data sharing statement as per the 
recommendations of the ICMJE. Statements are to indicate: 
• whether individual deidentified participant data will be shared; 
• what data in particular will be shared; whether additional, related documents will be 
available; 
• when the data will become available and for how long; by what access criteria data will be 
shared. 
  
Please see the ICJME announcement for further details and illustrative examples of data 
sharing statements: ICMJE Data Sharing Statements for Clinical Trials 
  
Since 1st December 2005, all clinical trials conducted in South Africa have been required to 
be registered in the South African National Clinical Trials Register. The SAMJ therefore 
requires that clinical trials be registered in the relevant public trials registry at or before the 
time of first patient enrollment as a condition for publication. The trial registry name and 
registration number must be included in the manuscript. 
  
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
  
Patient Consent 
Information that would enable identification of individual patients should not be published 
in written descriptions, photographs, and pedigrees unless the information is essential for 
scientific purposes and the patient (or parent or guardian) has given informed written 
consent for publication and distribution. We further recommend that the published article is 
disseminated not only to the involved researchers but also to the patients/participants from 
whom the data was drawn. Refer to Protection of Research Participants. The signed 





Any individual who is identifiable in an image must provide written agreement that the 
image may be used in that context in the SAMJ. 
  
Copyright notice 
Copyright remains in the Author’s name. The work is licensed under a Creative Commons 
Attribution - Noncommercial Works License. Authors are required to complete and sign 
an Author Agreement form that outlines Author and Publisher rights and terms of 
publication. The Author Agreement form should be uploaded along with other 
submissions files and any submission will be considered incomplete without it. 
  
Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
main findings of your paper have been presented at a conference and published in abstract 
form, to avoid copyright infringement. All research already published as ‘Conference 
proceedings’ needs to be substantially re-written, with a new title, a new abstract and new 
and important results to back up any study before it will be considered for a new 
publication. The SAMJ does not hold itself responsible for statements made by the authors. 
Previously published images 
If an image/figure has been previously published, permission to reproduce or alter it must be 
obtained by the authors from the original publisher and the figure legend must give full 
credit to the original source. This credit should be accompanied by a letter indicating that 
permission to reproduce the image has been granted to the author/s. This letter should be 




The SAMJ is committed to protecting the privacy of its website and submission system 
users. The names, personal particulars and email addresses entered in the website or 
submission system will not be made available to third parties without the user’s permission 
or due process. By registering to use the website or submission system, users consent to 
receive communication from the SAMJ or its publisher HMPG on matters relating to the 




Use of racial or ethnicity classifications in research is fraught with problems. If you choose 
to use a research design that involves classification of participants based on race or 
ethnicity, or discuss issues with reference to such classifications, please ensure that you 
include a detailed rationale for doing so, ensure that the categories you describe are 
carefully defined, and that socioeconomic, cultural and lifestyle variables that may underlie 
perceived racial disparities are appropriately controlled for. Please also clearly specify 
whether race or ethnicity is classified as reported by the patient (self-identifying) or as 
perceived by the investigators. Please note that is not appropriate to use self-reported or 
investigator-assigned racial or ethnic categories for genetic studies. 
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Continuing Professional Development (CPD) 
SAMJ is an HPCSA-accredited service provider of CPD materials. Principal authors can 
earn up to 15 CPD continuing education units (CEUs) for publishing an article; co-authors 
are eligible to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. Each 
month, SAMJ also publishes a CPD-accredited questionnaire relating to the academic 
content of the journal. Successful completion of the questionnaire with a pass rate of 70% 
will earn the reader 3 CEUs. Administration of our CPD programme is managed by Medical 




Preparing an article for anonymous review 
  
To ensure a fair and unbiased review process, all submissions are to include an anonymised 
version of the manuscript. The exceptions to this are Correspondence, Book reviews and 
Obituary submissions. 
  
Submitting a manuscript that needs additional blinding can slow down your review process, 
so please be sure to follow these simple guidelines as much as possible: 
• An anonymous version should not contain any author, affiliation or particular institutional 
details that will enable identification. 
• Please remove title page, acknowledgements, contact details, funding grants to a named 
person, and any running headers of author names. 
• Mask self-citations by referring to your own work in third person 
General article format/layout 
Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word format. Text must be single-spaced, in 12-point 
Times New Roman font, and contain no unnecessary formatting (such as text in boxes). 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) and 
contact details of ALL authors must be provided in the manuscript and in the online 
submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
• Include sections on Acknowledgements, Conflict of Interest, Author Contributions and 
Funding sources. If none is applicable, please state ‘none’.  
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• Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' but '50%' 
and '19ºC'. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B for 
beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
• Round brackets (parentheses) should be used, as opposed to square brackets, which are 
reserved for denoting concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the text. You may use the table 
format –this is the only exception. Please DO NOT use fill, format lines and so on. 
  
SAMJ is a generalist medical journal, therefore for articles covering genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, although 
they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ can 
be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
• Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
• HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
• OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
• Bennet et al. Standardized human pedigree nomenclature: Update and assessment of the 
recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 




• In Practice and Case reports 
• Reviews 
• Clinical trials 
• Correspondence 
• Obituaries 




Guideline word limit: 4 000 words 
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Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that 
clearly lay out the rationale for conducting the study. Some common reasons for conducting 
a study are: to fill a gap in the literature, a logical extension of previous work, or to answer 
an important clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study methods in as 
much detail as possible so that others would be able to replicate the study should they need 
to. Results should describe the study sample as well as the findings from the study itself, but 
all interpretation of findings must be kept in the discussion section, which should consider 
primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The 
conclusion should briefly summarise the main message of the paper and provide 
recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
  
Structured abstract 
• This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
o Methods: must include study design, number of participants, description of the intervention, 
primary and secondary outcomes, any specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample description; outline the results 
according to the methods described. Primary outcomes must be described first, even if they 
are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
• Do not include any references in the abstracts. 
  
  
Here is an example of a good abstract. 
  
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
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• Objectives (within Introduction/Background): a clear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational attainment, co-existing disease 
indicators, etc)that may have an impact on the study results. Clearly define how participants 
were enrolled, and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically for 
randomised controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key characteristics of 
comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, 
the exact level of statistical significance and the number need to treat/harm. Whenever 
possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is to present 
this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean 
(SD). 
• Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 




Guideline word limit: 1 000 words 
  
These opinion or comment articles are usually commissioned but we are happy to consider 
and peer review unsolicited editorials. Editorials should be accessible and interesting to 
readers without specialist knowledge of the subject under discussion and should have an 
element of topicality (why is a comment on this issue relevant now?) There should be a 
clear message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
• expert opinion 
• personal clinical experience 
• observational studies 
• trials 
• systematic reviews. 
  
CME (by invite only) 
CME is intended to provide readers with practical, up-to-date information on medical and 
related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to adhere 
strictly to the guidelines on word count as we have a page limit for the print issue of 
the SAMJ. We reserve the right to place some tables and reference lists online if this is 
necessary for space. 
In practice, this means that each CME topic usually covers two issues of the print issue of 
the SAMJ. 
  
The guest editor, in consultation with the editor, is responsible for convening a team of 
authors, deciding on the subjects to be covered and for reviewing the manuscripts submitted. 
The suggestion is for 4 - 5 articles, although there is some room for flexibility contingent on 
discussions with the editor. 
  
For queries about these guidelines please feel free to contact the CME editor, Dr Bridget 
Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)82 452 2860) 
  
Review process 




Guideline word limit: 1 000 words 
• Include the guest editor’s personal details (qualifications, positions, affiliation, e-mail 
address, and a short personal profile (50words)). 
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• If possible, include a photograph of the author(s) at high enough resolution for print. It is 
preferable to provide two guest editorials, one for each issue, so that the content of the 
articles in each issue is covered. 
  
Articles 
Guideline word limit: 2 000 - 3 000 words 
• Each article requires an abstract of ±200 words. 
• The editor reserves the right to shorten articles but will send a substantially shortened article 
back for author approval. 
  
Personal details 
Please supply: Your qualifications, position and affiliations and MP number (used for CPD 
points); Address, telephone number and fax number, and your e-mail address; and a short 
personal profile (50words)and a few words about your current fields of interest. 
  
In Practice 
Guideline word limit: 2 000 - 3 000words 
  
This section includes articles that would previously have been accepted into the Forum 
section, and case reports. 
In practice articles are those that draw attention to specific issues of clinical, economic or 
political interest regarding medicine and healthcare in southern Africa. They are assigned to 
a topic: 
  
• Case report 
• Clinical practice 
• Clinical alert 
• Issues in medicine 
• Issues in public health 
• Healthcare delivery 
• Medicine and the environment 
• Medicine and the law 
• Cochrane corner 
  
  
An In Practice article should follow the following format – sub-headings are not necessary, 
but may be used for clarity: 
• Author affiliations and qualifications: to be the same as for Research. Provide all authors’ 
names and initials, qualifications and full affiliations, and corresponding author. 
• Short abstract: does not need to be structured, but should capture the essential features of the 
article 
• Introduction: the reason for the article and the issue being addressed 
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• Recent research, discussion, local policy around the issue – include your own research where 
appropriate 
• All statements should be referenced and, if opinion only, this should be stated 
• Discussion: how this article adds to the discussion around a particular topic 
• If a clinical practice or policy point is at issue, this needs to be emphasised, using a box with 
highlights if appropriate. 
  
Essentially In practice is an opportunity for a more discursive approach to topics of clinical, 
economic or political importance in southern African health systems. It is not an opportunity 
to put forward unsubstantiated opinions! 
  
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from Africa, 
preferably southern Africa unless the condition is common to all African countries, and 
must be either a completely new description of a clinical condition or result (use Google!) or 
a case that highlights important practice or management issues. 
  
Please use the following format for case reports: 
• Title of case: do not include the words ‘a case report’ in the title 
• Summary/abstract:  up to 150 words summarising the case presentation and outcome 
• Background: why is this case important and why did you write it up? 
• Case presentation: presenting features, medical, social, family history as appropriate 
• Case management: should be according to best practice, and if not, please explain why 
• Investigations, if relevant: save space by simply saying ‘normal’ if, for example, renal 
function was completely normal, rather than listing normal results, highlight the abnormal – 
or indeed the normal if this is clinically significant 
• Differential diagnosis, if relevant 
• Treatment, if relevant 
• Outcome and follow-up 
• Discussion – a VERY BRIEF review of similar published cases 
• Teaching points: 3 - 5 bullet points 
• References: as per the SAMJ house style 
• Tables and figures: keep to a minimum. Use clinical images where relevant – we need hi-res 
versions for print, and identifiable persons must have a consent form 
• Patient consent: please include a statement about patient consent to a written case report. This 
should be uploaded as a supplementary file. 
  
Clinical trials 
Guideline word limit: 4000 words 
  
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should 
be registered with the appropriate national clinical trial registry (or any international 
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primary register, if relevant), and the trial registration number should be cited at the end of 
the abstract. Since 1st December 2005, all clinical trials conducted in South Africa have 
been required to be registered in the South African National Clinical Trials Register. 
The SAMJ therefore requires that clinical trials be registered in the relevant public trials 
registry at or before the time of first patient enrollment as a condition for publication. The 
trial registry name and registration number must be included in the manuscript. 
  
Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
  
Review articles 
Guideline word limit: 4 000 words 
  
These are welcome, but should be either commissioned or discussed with the Editor before 
submission. A review article should provide a clear, up-to-date account of the topic and be 
aimed at non-specialist hospital doctors and general practitioners. 
  
Please ensure that your article includes: 
• Abstract: unstructured, of about 100-150 words, explaining the review and why it is 
important 
• Methods: Outline the sources and selection methods, including search strategy and keywords 
used for identifying references from online bibliographic databases. Discuss the quality of 
evidence. 
• When writing: clarify the evidence you used for key statements and the strength of the 
evidence. Do not present statements or opinions without such evidence, or if you have to, say 
that there is little or no evidence and that this is opinion. Avoid specialist jargon and 
abbreviations, and provide advice specific to southern Africa. 
• Personal details: Please supply your qualifications, position and affiliations and MP number 
(used for CPD points); address, telephone number and fax number, and your e-mail address; 
and a short personal profile (50 words) and a few words about your current fields of interest. 
  
Correspondence (Letters to the Editor) 
Guideline word limit: 500 words 
  
Letters to the editor should relate either to a paper or article published by the SAMJ or to a 
topical issue of particular relevance to the journal’s readership 
  
• May include only one illustration or table 
• Must include a correspondence address. 
  
Book reviews 
Guideline word limit: 400 words 
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Should be about 400 words and must be accompanied by the publication details of the book. 
Provide a hi-res image of the cover if possible (with permission from the copyright holder). 
  
Obituaries 
Guideline word limit: 400 words 
Should be offered within the first year of the practitioner’s death, and may be accompanied 
by a photograph. 
  
Guidelines  
Guidelines should always be discussed with the Editor prior to submission. 
  
Because of the intensive review process required to ensure Guidelines are independent, 
evidence-based and free from commercial bias, they are usually published as a supplement 
to the SAMJ, the costs of which must be covered by sponsorship, advertising or payment by 
the guideline authors/association. We will provide a quote based on the expected length of 
the guideline and whether it is to appear online only, or in print, which must be accepted by 
the body putting the guidelines together before submitting the work to the SAMJ. 
  
The Editor reserves the right to determine the scheduling of supplements. Understandably, a 
delay in publication must be anticipated dependent upon editorial workflow. 
All guidelines should include a clear, transparent statement about all sources of funding and 
an explicit, clear statement of conflicts of interest of any of the participants in the guidelines 
about industry funding for lectures, research, conference participation etc.  
All guidelines should be structured according to Agree II. 
Please access this website before putting the guidelines together, download the Agree 11 
instrument and use this to put the guidelines together. 
All submitted guidelines will be sent to the local Agree II appraisal committee for review 
and must be endorsed by an appropriate body prior to consideration and all conflicts of 
interest expressed. 
  
A structured abstract not exceeding 400 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered 




• If illustrations submitted have been published elsewhere, the author(s) should provide 
consent to republication obtained from the copyright holder. 
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
• All images must be of high enough resolution/quality for print. 
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
• Ensure all graph axes are labelled appropriately, with a heading/description and units (as 
necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 
etc. 
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• Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to 
show the tumour. 
• Each image must be attached individually as a 'supplementary file' upon submission (not 
solely embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc. 
  
Tables 
• Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
• Large tables will generally not be accepted for publication in their entirety. Please consider 
shortening and using the text to highlight specific important sections, or offer a large table as 
an addendum to the publication, but available in full on request from the author 
• Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in 
the text. 
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
• Ensure each table has a concise title and column headings, and include units where necessary. 
• Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then 
** †† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
  
Rather: 
Each row of data must have its own proper row: 
  
Do not: use separate columns for n and %: 
  
Rather: 
Combine into one column, n (%): 
  
Do not: have overlapping categories, e.g.: 
  
Rather: 




NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
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• Authors must verify references from original sources. 
• Citations should be inserted in the text as superscript numbers between square brackets, e.g. 
These regulations are endorsed by the World Health Organization,[2] and others.[3,4-6] 
• All references should be listed at the end of the article in numerical order of appearance in the 
Vancouver style (not alphabetical order). 
• Approved abbreviations of journal titles must be used; see the List of Journals in Index 
Medicus. 
• Names and initials of all authors should be given; if there are more than six authors, the first 
three names should be given followed by et al. 
• Volume and issue numbers should be given. 
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
• Wherever possible, references must be accompanied by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
  
Some examples: 
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about 
glaucoma. Stat Med 1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182 
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 
1975:96-101. 
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading 
Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms 
of Disease. Philadelphia: WB Saunders, 1974:457-472. 
• Internet references: World Health Organization. The World Health Report 2002 - Reducing 
Risks, Promoting Healthy Life. Geneva: WHO, 2002. http://www.who.int/whr/2002 
(accessed 16 January 2010). 
• Legal references 
•              Government Gazettes: 
National Department of Health, South Africa. National Policy for Health Act, 1990 (Act No. 
116 of 1990). Free primary health care services. Government Gazette No. 17507:1514. 
1996. 
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the notice 
number in this Gazette. 
•              Provincial Gazettes: 
Gauteng Province, South Africa; Department of Agriculture, Conservation, Environment 
and Land Affairs. Publication of the Gauteng health care waste management draft 
regulations. Gauteng Provincial Gazette No. 373:3003, 2003. 
•              Acts: 
South Africa. National Health Act No. 61 of 2003. 
•              Regulations to an Act: 
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South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic 
medicine services. Government Gazette No. 35099, 2012. (Published under Government 
Notice R176). 
•              Bills: 
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006. 
•              Green/white papers: 
South Africa. Department of Health Green Paper: National Health Insurance in South 
Africa. 2011. 
•              Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another:  Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate Cape, (G) 
Gauteng, and so on. 
NOTE: no . after the v 
• Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher 
place: Publisher name, year; pages. 
• Cited manuscripts that have been accepted but not yet published can be included as 
references followed by '(in press)'. 
• Unpublished observations and personal communications in the text must not appear in the 
reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
  
From submission to acceptance 
Submission and peer-review 
To submit an article: 
• Please ensure that you have prepared your manuscript in line with the SAMJ requirements. 
• All submissions should be submitted via Editorial Manager 
• The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions for published 
images, etc. 
• Once the submission has been successfully processed on Editorial Manager, it will undergo a 
technical check by the Editorial Office before it will be assigned to an editor who will handle 
the review process. If the author guidelines have not been appropriately followed, the 








Please note that there is a 6-month waiting time for publication, once an article has been 
sent to the production team. 
The following process will follow: 
1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor 
(CE). 
2. The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for typesetting. 
3. If the CE has an author queries, he/she will contact the corresponding author and send 
them the copyedited Word doc, asking them to solve the queries by means of track 
changes or comment boxes. 
4. The authors are typically asked to respond within 1-3 days. Any comments/changes 
must be clearly indicated e.g. by means of track changes. Do not work in the original 
manuscript - work in the copyedited file sent to you and make your changes clear. 
5. The CE will finalise the article and then it will be typeset. 
6. Once typeset, the CE will send a PDF of the file to the authors to complete their final 
check, while simultaneously sending to the 2nd-eye proofreader. 
7. The authors are typically asked to complete their final check and sign-off within 1-2 
days. No major additional changes can be accommodated at this point. 
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8. The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
  
Changing contact details or authorship 





Online v. print  
The SAMJ is an online journal. The online version of the journal is the one that has the 
widest circulation, is indexed by bibliographic databases including PubMed and SciELO, 
and is accessible in academic libraries. A printed edition , containing material selected by 
the Editor is also published each month and distributed to the membership of the South 




• The full text of all accepted articles is published in full online, open access. 
• Citation information of each article is based on its online publication. 
• You may want to make use of the advantages of online publication e.g. specify web links to 
other sources, images, data or even a short video. 
  
Print 
• Not all articles will be selected for print. 
• An article may be selected for print in a different month from that in which it was published 
online. 
• Research articles will appear in abstract form only, if selected for a print edition. 
  
Errata and retractions  
Errata 
Should you become aware of an error or inaccuracy in yours or someone else’s contribution 
after it has been published, please inform us as soon as possible via an email to 
publishing@hmpg.co.za,including the following details: 
• Journal, volume and issue in which published 
• Article title and authors 
• Description of error and details of where it appears in the published article 
• Full detail of proposed correction and rationale 
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We will investigate the issue and provide feedback. If appropriate, we will correct the web 
version immediately, and will publish anerratum  in the next issue. The correction will be 
indexed, as PubMed has a function for linking errata back to the original article. All 
investigations will be conducted in accordance with guidelines provided by the Committee 
on Publication Ethics (COPE). 
  
Retractions 
Retraction of an article is the prerogative of either the original authors or the editorial team 
of HMPG. Should you wish to withdraw your article before publication, we need a signed 
statement from all the authors. 
  
Should you wish to retract your published article, all authors have to agree in writing before 
publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
• Journal, volume and issue to which article was submitted/in which article was published 
• Article title and authors 
• Description of reason for withdrawal/retraction. 
  
We will make a decision on a case-by-case basis upon review by the editorial committee in 
line with international best practices. Comprehensive feedback will be communicated with 
the authors with regard to the process. In case where there is any suspected fraud or 
professional misconduct, we will follow due process as recommended by the Committee on 
Publication Ethics (COPE), and in liaison with any relevant institutions. 
  
When a retraction is published, it will be linked to the original article. 
  
Indexing 
The SAMJ has an impact factor of 1.5. 
Published articles are covered by the following major indexing services. As such articles 
published in the SAMJ are immediately available to all users of these databases, guaranteed 
a global and African audience: 
• Index Medicus (Medline/PubMed)  
• ExcerptaMedica (EMBASE) 
• Biological Abstracts (BIOSIS) 
• Science Citation Index (SciSearch) 









Sponsored supplements  
Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
  
  
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that 
do not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. All research already published as ‘Conference proceedings’ needs to be 
substantially re-written, with a new title, a new abstract and new and important results 
to back up any study before it will be considered for a new publication. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word document format. The text is single-spaced, in 
12-point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (PDF or jpeg). These must be submitted individually as 'supplementary files' 
(not solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
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STARD stands for “Standard s for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the 
completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative 
study reports. Editors and peer-revie we rs can use it to evaluate whether the informa tion has been included in manuscri pts 
submitted for publication. 
 
EXPLANATION 
A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as having 
a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the 
future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a 
combination of these, or any other method for collecting information about the current health status of a patient. 
 
The test whose accuracy is evaluated is called index test. A study can evaluate the accuracy of one or more index tests. 
Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index 
test results with those of the reference standard. The reference standard is the best available method for establishing the 
presence or absence of the target condition. An accuracy study can rely on one or more reference standards. 
 
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the 
reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target 
condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative 
index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy 
statistics can be estimated, such as the positive and negative predictive values of the test. Confidence intervals around 
estimates of accuracy can then be calculated to quantify the statistical precision of the measurements. 
 
If the index test results can take more than two values, categorization of test results as positive or negative requires a test 
positivity cut-off. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) 
curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The 
area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test. 
 
The intended use of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The 
clinical role of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, 
replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test. 
 
Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical 
tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was 
not explicitly developed for these other outcomes , statistics , and study types, although most STARD items would still apply. 
 
DEVELOPMENT 
This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, 
researche rs , and editors. The guiding principle in the developmen t of STARD was to select items that, when reported, would 
help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of 
conclusions and recommendations. The list represents an update of the first version, which was published in 2003. 
 
More information can be found on http://www.equator-network.org/reporting-guidelines/stard. 
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 Section & Topic No Item 
 
 TITLE OR ABSTRACT   
 1 Identification as a study of diagnostic accuracy using at least one measure of accuracy 
(such as sensitivity, specificity, predictive values, or AUC) 
ABSTRACT   
 2 Structured summary of study design, methods, results, and conclusions 
(for specific guidance, see STARD for Abstracts) 
INTRODUCTION   
 3 Scientific and clinical background, including the intended use and clinical role of the index test 
 4 Study objectives and hypotheses 
METHODS   
Study design 5 Whether data collection was planned before the index test and reference standard 
were performed (prospective study) or after (retrospective study) 
Participants 6 Eligibility criteria 
 7 On what basis potentially eligible participants were identified 
(such as symptoms, results from previous tests, inclusion in registry) 
 8 Where and when potentially eligible participants were identified (setting, location and dates) 
 9 Whether participants formed a consecutive, random or convenience series 
Test methods 10a Index test, in sufficient detail to allow replication 
 10b Reference standard, in sufficient detail to allow replication 
 11 Rationale for choosing the reference standard (if alternatives exist) 
 12a Definition of and rationale for test positivity cut-offs or result categories 
of the index test, distinguishing pre-specified from exploratory 
 12b Definition of and rationale for test positivity cut-offs or result categories 
of the reference standard, distinguishing pre-specified from exploratory 
 13a Whether clinical information and reference standard results were available 
to the performers/readers of the index test 
 13b Whether clinical information and index test results were available 
to the assessors of the reference standard 
Analysis 14 Methods for estimating or comparing measures of diagnostic accuracy 
 15 How indeterminate index test or reference standard results were handled 
 16 How missing data on the index test and reference standard were handled 
 17 Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory 
 18 Intended sample size and how it was determined 
RESULTS   
Participants 19 Flow of participants, using a diagram 
 20 Baseline demographic and clinical characteristics of participants 
 21a Distribution of severity of disease in those with the target condition 
 21b Distribution of alternative diagnoses in those without the target condition 
 22 Time interval and any clinical interventions between index test and reference standard 
Test results 23 Cross tabulation of the index test results (or their distribution) 
by the results of the reference standard 
 24 Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals) 
 25 Any adverse events from performing the index test or the reference standard 
DISCUSSION   
 26 Study limitations, including sources of potential bias, statistical uncertainty, and generalisability 
 27 Implications for practice, including the intended use and clinical role of the index test 
OTHER INFORMATION   
 28 Registration number and name of registry 
 29 Where the full study protocol can be accessed 
 30 Sources of funding and other support; role of funders 
